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Abstract 
Inherited retinal diseases include a number of disorders which typically affect photoreceptor and/or 
retinal pigment epithelial function, and can often lead to severe visual impairment.  Advances in 
several key disciplines have enabled therapeutic strategies to be developed and applied, in an 
attempt to provide relief from a range of previously untreatable and debilitating conditions.  Specific 
advances include developments in molecular genetics which have allowed the identification of many 
of the genes responsible for particular conditions, and progress in viral gene transfer technology 
which has enabled the transport and replacement of specific genes into targeted regions of the 
retina.   
One of the first human clinical trials of gene therapy for inherited retinal disease was carried out at 
Moorfields Eye Hospital and UCL Institute of Ophthalmology, just prior to two similar trials 
conducted in the United States. This trial involved 12 patients with RPE65 deficiency - an early-onset 
retinal dystrophy, known as Leber Congenital Amaurosis.  The results from this trial are described 
and provide encouraging evidence of the safe administration of viral vectors in the eye, and also 
demonstrate improvements in retinal function in a number of patients.  However, the extent and 
duration of the response did not match that observed in prior animal studies, suggesting 
improvements in gene expression level may be required in humans.  In addition, careful 
consideration for future involvement of the foveal region is highlighted, since retinal thinning was 
observed in a number of patients following subretinal delivery; a finding also observed in the two 
RPE65 gene replacement trials conducted in the United States.  
Achromatopsia is an inherited disorder of congenitally absent cone photoreceptor function resulting 
in poor visual acuity, absent/markedly reduced colour vision and photophobia.  Gene replacement 
therapy in animal models of achromatopsia has shown evidence of restored cone function, 
suggesting that this condition may be an appropriate target for gene therapy in humans.  Recent 
studies have suggested that achromatopsia is a progressive condition with deterioration in cone 
structure with age, implying that the window of opportunity for therapeutic intervention may be 
narrow.  In this study of retinal structure and function (in preparation for a gene therapy trial) in 40 
patients with achromatopsia, an age-associated deterioration in cone photoreceptor structure was 
not identified, suggesting that the age range for potential intervention is wider than recently 
suggested, and prospective patients should be assessed on an individual basis, irrespective of age. 
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1.1 Retinal anatomy and function 
The retina is the photosensitive tissue within the eye (Fig. 1) that is responsible for receiving and 
converting light stimulus into neuronal impulses, which then leave the eye via the optic nerve.  It is a 
10-layer structure (Fig. 2), and can be broadly divided into the inner neurosensory retina, and outer 
supporting layer of cells - the retinal pigment epithelium (RPE). There are 3 principal cell types that 
make up the neurosensory retina – photoreceptors, bipolar cells and ganglion cells, and their activity 
is modulated by other cell types, such as horizontal and amacrine cells.  Photoreceptors are the cells 
that respond to light and there are 2 subtypes in the human retina: rods and cones (Fig. 3).  Rods are 
sensitive to low light levels and are responsible for scotopic (night) and peripheral vision.  Cones 
contribute to fine resolution, visual acuity and colour vision.  In the adult retina, there are 
approximately 90 million rod and 5 million cone cells, and their distribution varies in different 
regions of the retina.  The peripheral retina is mostly rod dominated with approximately 30,000 cells 
per mm2, whereas cones are most densely packed (150,000 per mm2) in the central retina (macula).  
The macula is approximately 5 mm in diameter and located 3 mm lateral to the optic disc.  The 
central portion of the macula is called the fovea centralis, and in this region, inner retinal cells are 
laterally displaced, thereby allowing maximum incident light to be absorbed by the underlying 
photoreceptors. 
Photoreceptors consist of an inner and outer segment, a connecting cilium, a cell body that contains 
the nucleus, and a synaptic region (Fig. 3).  The inner segments are densely packed with 
mitochondria and provide the metabolic requirements required for the conversion of light into 
electrical impulses.  A cilium acts as a conduit for metabolites and lipids between the inner and outer 
segments.  The outer segments of rods and cones are shaped as their names imply, and contain the 
visual pigments responsible for light absorption. In cones, the outer segments are made up of 
invaginations known as lamellae that are continuous with the inter-photoreceptor space.  In rods, 
the invaginations undergo further folding to form a column of membranous discs which are 
surrounded by a plasma membrane.  The cell bodies of rod and cone cells are located in the outer 
nuclear layer (ONL).   
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Fig. 1 – Structure of the human eye; schematic diagram showing features of the human eye (from 
www.advancedfunctionalanatomy.com) 
Fig. 2 – Schematic of the various retinal layers and cells (from 
www.advancedfunctionalanatomy.com) 
Fig. 3 – Rod and Cone photoreceptor cells; schematic diagram showing rod and cone structure (from 
www.thebrain.mcgill.ca) 
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Photoreceptors synapse with bipolar cells, which are located in the inner nuclear layer (INL).  Cones 
make connections with two distinctly different types of bipolar cell: one type is called the ON-bipolar cell 
because it is depolarised by light, and the other is called the OFF-bipolar because it is hyperpolarized by 
light. There are further sub-divisions amongst bipolar cells, including the finding that S-cones appear to 
synapse with different bipolars than the L-/M- cones. Rods are sub served by their own bipolar cells 
which form connections with as many as 50 rod photoreceptors.  Signals are then transmitted to the 
ganglion cells whose cell bodies are found in the ganglion cell layer (GCL).  Ganglion cell axons form the 
nerve fibre layer which then allows impulses to leave the eye via the optic nerve.  Supporting retinal 
cells include amacrine and horizontal cells, and these have a role in the modulation of signals reaching 
the ganglion cells.  Müller cells are the principal supporting glial cells of the retina and surround blood 
vessels and cell bodies, providing essential nutrients and survival factors.    
The RPE lies posterior to the photoreceptor outer segments and consists of a monolayer of cuboidal 
cells, whose basal aspect lies on a connective tissue layer known as Bruch’s membrane.  The apical 
aspect of the RPE has microvilli that invaginate the photoreceptor outer segments.  The RPE provides 
multiple supportive functions to the neurosensory retina including phagocytosis of photoreceptor 
outer segments; providing photoreceptor trophic support in the form of various growth factors; 
synthesis of inter-photoreceptor matrix; providing a selectively permeable barrier between the 
choroid and neurosensory retina; renewal of retinoids which are an integral part of photoreception; 
and reduction of light scatter within the eye by light absorption. 
The retina has the highest oxygen consumption per weight of any human tissue.  It receives a dual 
blood supply with the inner two-thirds receiving nourishment from branches of the central retinal 
vessels, and the outer one-third receiving its supply from the choroidal circulation. 
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1.2 Phototransduction  
Phototransduction is the conversion of light into electrical responses, which are then conveyed to 
the optic nerve, and ultimately to the visual cortex.  Rod and cone photoreceptors play an integral 
part in the phototransduction cascade as they contain visual pigments which are able to absorb light 
photons.  Rhodopsin and cone opsins are the visual pigments in rods and cones, respectively.  These 
are G-protein coupled receptors (GPCR) which consist of seven transmembrane domains, with the 
peak sensitivity for rhodopsin being approximately 496nm, whilst the cone opsin peaks are about 
420nm, 530nm and 560nm for short (blue), middle (green) and long (red) wavelength sensitive 
pigments respectively.  The opsins all contain and utilise the same chromophore, 11-cis retinal, 
which isomerises to all-trans retinal when stimulated by photons.  This causes a conformational 
change in the GPCR tertiary structure and an intra-photoreceptor signalling pathway, the 
phototransduction cascade, is initiated (Fig. 4).  The “activated” opsin causes activation of the 
transducin molecule, which allows the Ƴ subunit of the phosphodiesterase (PDE) enzyme to be 
released from its αβ complex, which then hydrolyses cyclic guanosine monophosphate (cGMP) to 
5’GMP.  The lower intracellular concentration of cGMP causes a closure of cGMP-dependent cation 
channels, preventing the influx of cations and resulting in the closure of voltage-gated Ca2+ channels.  
This leads to photoreceptor hyperpolarisation and prevents the release of the neurotransmitter 
glutamate (which is normally continually released in non-stimulated conditions).  The reduced 
glutamate level is detected by post-synaptic bipolar cells, which in turn depolarise or hyperpolarise 
their own synaptic membranes, depending on whether they are ON- or OFF- bipolar cells 
respectively.  
Termination of the phototransduction cascade requires restoration of intracellular cGMP and Ca2+ 
levels including opening of Na+/ Ca2+ channels.  Reduced intracellular Ca2+ following light stimulus 
causes activation of guanylate cyclase activating proteins (GCAP I and II).  GCAP proteins bind to the 
intracellular domain of retinal guanylate cyclase (RetGC), initiating the resynthesis of cGMP.  The 
increase in cGMP levels allows cGMP to bind to and reopen the cationic channels, restoring the 
photoreceptor to its initial depolarised dark state. Photorecovery is also facilitated by the 
deactivation of rhodopsin by rhodopsin kinase (RK) located at the outer segment disc membrane.  
RK phosphorylates serine residues in the cytoplasmic loops of activated rhodopsin molecules, 
allowing a second photorecovery protein, Recoverin, to bind.  This prevents transducin being bound 
to phosphorylated rhodopsin and halts downstream signalling in the phototransduction cascade.  
A key feature of phototransduction is the amplification of signal that can be achieved at each stage 
of the cascade.  One isomerised rhodopsin molecule is able to activate hundreds of transducin 
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molecules, and activated transducin then allows PDE to hydrolyse cGMP molecules.  This leads to the 
hyperpolarisation of the photoreceptor by approximately 1mV and therefore only a few light 
photons are required for photoreceptors to become hyperpolarised. 
 
 
 
Fig. 4 – Schematic representation of the phototransduction cascade –from Smith et al. (1). (i) light 
is absorbed by and activates opsin (ii) activated opsin causes activation of transducin which then 
activates phosphodiestersae (PDE) by release of its Ƴ subunit (iii) Activated PDE catalyses the 
hydrolysis of cGMP to 5’GMP and reduced cGMP levels closes cGMP-gated channels and subsequent 
cell hyperpolarisation (iv) Reduced Ca2+ levels stimulates Ca2+ release from and activates recoverin, 
which then activates rhodopsin kinase and in turn phosphorylates (P) opsin. Arrestin then returns 
opsin to its inactive state.  Lower Ca2+ also activates retinal guanylate cyclase (RetGC) (v) RetGC 
increases cGMP concentration which opens cGMP-gated channels, allowing an influx of ions and 
depolarising the cell. 
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1.3 The visual cycle 
The visual cycle (Fig. 5) is essentially a series of enzymatic reactions that primarily take place in the 
RPE, and it facilitates the recycling of all-trans retinal back to 11-cis retinal, therefore allowing 
photoreceptors to function during many hours of continuous light stimulation.  In rod 
photoreceptors, the visual cycle begins with the release of all-trans retinal from activated rhodopsin, 
and all-trans retinal is transported into the cytoplasm by ATP-binding cassette protein in the retina 
(ABCA4).  All-trans retinal is then converted to all-trans retinol in the photoreceptor cytoplasm by 
retinol dehydrogenase (RDH).  All-trans retinol is then bound to inter-photoreceptor retinoid binding 
protein (IRBP) and transferred to the RPE.  Once in the RPE, all-trans retinol is bound to the 
intracellular transporter protein CRBP1, and is esterified to form all-trans retinyl ester by lecithin 
retinol acyltransferase (LRAT).  Following this, all-trans retinyl ester is converted to 11-cis retinol by 
the isomerohydrolase, RPE65.  Finally, 11-cis retinol is oxidised to 11-cis retinal and transported by 
IRBP to the photoreceptor, where it can re-associate with rhodopsin. 
In addition to the aforementioned visual cycle, cone photoreceptors also utilise an alternative 
pathway for opsin regeneration which involves Müller cells.  In this visual cycle, all-trans retinol 
leaves the cone cell and is absorbed by Müller cells, where it is converted to 11-cis retinol by all-
trans retinol isomerase with the aid of palmitoyl-CoA as an acyl donor.  11-cis retinol is transported 
to the cones by IRBP, where it is oxidised back to 11-cis retinal (by a cone specific 11-cis RDH) and 
combines with cone opsin to form the cone pigment (2, 3).  Two features of this alternative visual 
cycle assist in cones remaining responsive at almost any level of illumination, since a degree of their 
visual pigment is almost always regenerated.  Firstly, the alternative pathway is approximately 20-
fold faster than the RPE-mediated pathway, and secondly, rods are unable to use the alternative 
pathway as they are unable to oxidise 11-cis retinol to 11-cis retinal.  This prevents isomerised 
retinoids from being utilised by rods under daylight conditions when rod vision is less useful (2). 
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Fig. 5 – Schematic representation of the visual cycle – from Smith et al. (1). Activation of rhodopsin 
by light occurs through isomerisation of the bound chromophore, 11-cis-retinal, to all-trans retinal. 
Whilst the phototransduction cascade continues, all-trans retinal is transported to the cytoplasm by 
ABCA4. After modification by retinol dehydrogenase (RDH) to all-trans retinol, it is transported to 
the RPE and trans-isomerised to 11-cis-retinal by the actions of LRAT, RPE65 and 11-cis-RDH. 11-cis-
retinal is then transported back to the photoreceptor by inter-photoreceptor retinoid binding 
protein (IRBP), where it binds to rhodopsin, rendering it light sensitive. 
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1.4 Inherited Retinal Disorders 
The inherited retinal disorders are a heterogeneous group of conditions in which an underlying gene 
defect leads to retinal dysfunction and/or degeneration. They represent a significant cause of 
blindness (see Table 1).  They can be classified according to the mode of inheritance, principal site of 
retinal dysfunction (rod, cone, RPE, inner retina), extent of dysfunction (isolated macular disorder or 
generalised retinal dysfunction), typical age of onset, rate of progression, underlying gene defect, 
and association with systemic syndromes.  A hallmark of inherited retinal disorders is the genetic 
and clinical heterogeneity; with mutations in the same gene known to cause different diseases, and 
similar phenotypes can be associated with sequence variants in different genes. 
Disorders of rod function can be divided into stationary and progressive conditions.  Such patients 
experience difficulties with night vision and peripheral visual field loss.  In progressive disease there 
is subsequent cone system dysfunction resulting in impaired visual acuity, reduced colour vision and 
central scotomata.  The vast majority of progressive retinal disorders (retinal dystrophies) have a 
degree of both rod and cone involvement over time, and are therefore termed rod-cone or cone-rod 
dystrophies, depending on which photoreceptor type is predominantly affected in the early stages 
(see Fig. 6).  
Retinitis pigmentosa (RP) is the most common inherited retinal disorder, affecting approximately 1 in 
3,000 individuals and represents a generalised, progressive group of conditions. Rods are affected 
initially with cone cells involved later in the disease process.  The characteristic fundus appearance is 
optic pallor, retinal vessel attenuation and retinal pigmentation including “bone spicule” formation, 
believed to be due to the migration of RPE cells, following photoreceptor death.  Over 40 genes have 
been associated with non-syndromic RP with approximately 50-60% of RP cases showing either 
autosomal recessive (AR) or sporadic inheritance, 30-40% show autosomal dominant (AD) and 5-20% 
show X-linked (XL) inheritance (4).  An earlier age of onset and more severe disease is typically found 
in XL and AR cases, compared to ADRP; however there can be considerable variability in fundus 
appearance, progression and final visual function, both within and between families. 
Disorders of cone function can also be divided into stationary and progressive conditions.  Stationary 
disorders such as achromatopsia (ACHM) typically present shortly after birth or in early infancy, with 
nystagmus, photoaversion, reduced visual acuity and defective colour vision. Whereas, progressive 
cone dystrophies usually present in childhood or early adult life, with many patients developing rod 
involvement in later life, therefore leading to considerable overlap between progressive cone 
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dystrophies (CD) and cone-rod dystrophies (CRD).   Approximately 20 genes have been associated 
with CD or CRD and are inherited in either, AD, AR or XL patterns (5).   
Retinal disorders primarily affecting the macula include Stargardt disease and Best disease.  Stargardt 
disease, an AR disorder is the commonest form of childhood macular dystrophy (6).  The age of onset 
is usually in early teens, but there is wide variation, with a later age of onset being associated with a 
better visual prognosis. Patients present with impaired visual acuity caused by macular atrophy that 
is usually associated with yellow-white flecks at the level of the RPE.  Visual loss may precede any 
fundus changes and progression is variable, but usually declines to 1.0 logMAR or 1.30 logMAR (7).  
The causative gene, ABCA4, encodes a transporter protein which plays a key role in the visual cycle, 
with impaired ABCA4 function leading to an accumulation in the RPE of the toxic metabolite A2E (N-
retinylidene-N-retinylethanolamine), a major fluorophore of lipofuscin. Overtime, A2E-associated 
cytotoxicity is believed to cause RPE dysfunction and cell death, with subsequent photoreceptor cell 
loss. 
Best disease is a highly variable, predominantly AD macular dystrophy that is characterised by a 
round or oval yellow subretinal macular deposit.  The yellow material is due to an accumulation of 
lipofuscin throughout the RPE (8), which may resorb over time, leaving an area of RPE atrophy that 
may be complicated by the development of choroidal neovascularisation with acute visual loss 
and/or subretinal fibrosis.  The electro-oculogram (EOG) shows a very reduced or absent light rise, 
indicating widespread RPE dysfunction whilst the electroretinogram (ERG) is normal.  Onset is 
usually in childhood and visual prognosis is generally good, with most affected individuals retaining 
reading vision into the fifth decade or beyond.  Best disease is associated with missense mutations in 
the BEST1 gene (9), encoding the protein bestrophin, which has been localised to the basolateral 
plasma membrane of the RPE, and is believed to form a calcium-activated chloride channel, 
responsible for maintaining chloride conductance and regulating fluid transport across the RPE (10). 
Although most forms of Best disease show autosomal dominant inheritance, recently there have 
been reports of autosomal recessive forms of the disease (autosomal recessive bestrophinopathy) in 
which patients show reduced visual acuity (from 20/60 to 20/200), diffuse irregularity of the RPE 
with dispersed punctate flecks, and macular oedema or subretinal fluid. In addition to an abnormal 
EOG, the full-field ERG is also reduced, indicating more widespread photoreceptor impairment (11). 
Leber Congenital Amaurosis (LCA) represents a group of early onset, severe retinal dystrophies 
which can affect both rod and cone function, and is discussed in more detail later (section 1.6). 
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Disease Category Total No. of Genes and Loci No. of Identified Genes 
Bardet-Biedl syndrome, autosomal recessive  13  13  
Chorioretinal atrophy or degeneration, autosomal 
dominant  
1  1  
Cone or cone-rod dystrophy, autosomal dominant  8  5  
Cone or cone-rod dystrophy, autosomal recessive  8  7  
Cone or cone-rod dystrophy, X-linked  1  0  
Congenital stationary night blindness, autosomal dominant  1  1  
Congenital stationary night blindness, autosomal recessive  8  8  
Congenital stationary night blindness, X-linked  2  2  
Leber congenital amaurosis, autosomal dominant  1  1  
Leber congenital amaurosis, autosomal recessive  9  8  
Macular degeneration, autosomal dominant  13  7  
Macular degeneration, autosomal recessive  2  2  
Ocular-retinal developmental disease, autosomal 
dominant  
1  1  
Optic atrophy, autosomal dominant  5  2  
Optic atrophy, autosomal recessive  2  1  
Optic atrophy, X-linked  1  0  
Retinitis pigmentosa, autosomal dominant  19  18  
Retinitis pigmentosa, autosomal recessive  26  23  
Retinitis pigmentosa, X-linked  6  2  
Syndromic/systemic diseases with retinopathy, autosomal 
dominant  
9  8  
Syndromic/systemic diseases with retinopathy, autosomal 
recessive  
34  29  
Syndromic/systemic diseases with retinopathy, X-linked  3  2  
Usher syndrome, autosomal recessive  11  9  
Other retinopathy, autosomal dominant  10  5  
Other retinopathy, autosomal recessive  16  13  
Other retinopathy, mitochondrial  7  7  
Other retinopathy, X-linked  8  7  
TOTALS  225  182  
 
Table 1- Number of genes causing inherited retinal dystrophies according to disease category 
(RetNet; updated April 19th, 2013) 
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Fig. 6 – Categorisation of various types of retinal dystrophies according to principal photoreceptor 
type involved – adapted from den Hollander et al.(12). STGD = Stargardt disease, ACHM = 
achromatopsia, CD = cone dystrophy, CRD = cone rod dystrophy, LCA = Leber Congenital Amaurosis, 
RP = retinitis pigmentosa. 
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1.5 Mechanisms of Photoreceptor Cell Death  
Although a large number of different gene mutations can result in photoreceptor degeneration, the 
final pathway leading ultimately to photoreceptor cell death is similar, and involves both caspase-
dependent and caspase-independent mechanisms (13).  Dysregulation of photoreceptor intracellular 
calcium concentration is central to the initiation of apoptosis in retinal dystrophies.  In the (rd) 
mouse model, a null mutation in the Pde6b gene leads to loss of PDE activity, with resulting 
elevation in intracellular cGMP levels.  This causes an influx of calcium ions that resembles an 
environmental exposure of continuous darkness (so called “equivalent dark” hypothesis) resulting in 
rapid photoreceptor degeneration and apoptotic cell death (14).   
An alternative mechanism of photoreceptor death in retinal dystrophies is the “equivalent light” 
hypothesis.  This proposes that certain mutations lead to an overstimulation of the 
phototransduction cascade, causing signals to be sent to the inner retina that are equivalent to 
those sent in response to the detection of incident light (15, 16).  Evidence to support the equivalent 
light hypothesis includes findings from the Rpe65-/- mouse, in which rod photoreceptors display 
behaviour similar to that observed if they were exposed to continuous background light, with 
reduced circulating current in response to light stimulation and reduced light sensitivity (17).  A state 
of constant hyperpolarisation may lead to cell toxicity and photoreceptor death by either an intrinsic 
or extrinsic mechanism.  An ‘equivalent light’signal (and overstimulation of the phototransduction 
cascade) may result in significant lowering of normally tightly regulated intracellular calcium levels.  
In addition, an increase in oxidative stress may arise because a decrease in photoreceptor metabolic 
activity is not matched with a reduced choriocapillaris blood supply (due to the inability of these 
vessels to constrict); there may thereby be an increase in mitochondrial free radical production in 
the form of reactive oxygen species. 
In contrast, the extrinsic mechanism accounting for photoreceptor cell death involves a disturbance 
in secondary messenger release from cells in the inner retina.  Under normal response 
circumstances, bipolar cells, Müller cells and ganglion cells secrete neurotrophic factors that 
promote the survival of photoreceptors following injury.  However, following prolonged light 
stimulation, activated microglia invade the degenerating photoreceptor layer and alter the inner 
retinal expression of neurotrophic factors, including nerve growth factor (NGF), ciliary neurotrophic 
factor  (CNTF) and glial cell line-derived neurotrophic factor (GDNF) (18).   
14 
 
Progress in the understanding of the mechanisms of photoreceptor cell death in inherited retinal 
degeneration is ongoing and represents an important avenue of research in the development of 
therapeutic agents to modify or arrest these common disease pathways. 
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1.6 Leber Congenital Amaurosis 
LCA is a term used to describe a group of recessively inherited, severe, early-onset retinal 
dystrophies.  LCA affects approximately 1/81000 individuals (19), and accounts for approximately 5% 
of cases of inherited retinal dystrophies and 40% of children who attend schools for the blind (20)  
(21).    
To date, 17 genes have been associated with LCA and a causative gene mutation is found in 60-70% 
of cases (4), (22).  LCA genes are involved in a wide variety of retinal functions including 
photoreceptor morphogenesis (CRB1, CRX), phototransduction (AIPL1, GUCY2D), vitamin A recycling 
(LRAT, RDH12, RPE65), guanine synthesis (IMPDH1), and photoreceptor ciliary transport processes 
(MERTK, CEP290, LCA5, RPGRIP1, TULP1).  
The aforementioned genetic heterogeneity is matched by phenotypic variability; although in certain 
cases the genetic defect can be associated with a characteristic phenotype e.g. CRB1 and RDH12-
associated LCA (Table 2).  Affected children typically have poor vision from birth or within the first 
year, nystagmus, eye rubbing, sluggish pupil reactions and reduced or extinguished scotopic and 
photopic ERG responses.  Fundus appearance is variable, and can be normal at presentation, but 
there may be typical fundus features associated with particular genotypes (Fig. 7).   
GUCY2D is localised to the outer segments of rod and cone photoreceptors. It encodes a membrane 
guanylate cyclase, RetGC-1, an enzyme involved in the resynthesis of cGMP required for the 
recovery of the dark state after phototransduction. Patients have very poor vision from birth (from 
1.0 logMAR to light perception), photophobia, and high hypermetropia (>+5D) may be present.  
Fundus appearance is generally normal, although pigmentary changes and macular atrophy may 
occur.  Relatively intact cone photoreceptors at aged 7 years have been detected using optical 
coherence tomography (OCT) imaging (23). 
Aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) is expressed during both rod and cone 
development and plays a role in photoreceptor viability in the mature retina. More specifically, AIPL1 is 
necessary for the assembly of the catalytic alpha-subunit of the phototransduction protein 
phosphodiesterase (24). AIPL1 mutations cause a severe LCA phenotype with very poor vision (light 
perception to 1.30 logMAR), variable hypermetropia, and nyctalopia. The fundus may initially be normal 
but progressive retinal changes occur, including pigmentary changes and macular atrophy.  Some patients 
may also develop keratoconus or cataracts (25). 
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Lebercillin is expressed in ciliated tissues, and although the exact mechanism is unknown, it is 
thought to be involved with intra-photoreceptor ciliary transport.  Lebercillin mutations are a rare 
cause of LCA and are associated with very poor vision (26).  Reported fundus changes have varied 
from macula coloboma-like lesions, optic nerve head drusen to normal appearing fundi (27, 28).  
RP GTPase Regulator interacting protein 1 (RPGRIP1) directly binds to the RP GTPase regulator 
(RPGR) and is thought to be involved with ciliary transport, with RPGRIP1 containing  two coiled-coil 
domains that are homologous to those found in proteins involved in vesicular trafficking (29).  
Patients have severe loss of vision from early infancy, and although the retina may initially appear 
normal, most patients develop pigmentary retinopathy with progressive visual loss.  
The cone-rod homeobox (CRX) gene encodes a homeobox transcription factor that is essential for 
the differentiation and maintenance of photoreceptor cells.  CRX acts with the eye-specific 
transcription factors, neural leucine-zipper (NRL) and homeobox protein RX in the transactivation of 
photoreceptor specific genes, regulating the high level expression of photoreceptor outer segment 
proteins such as rhodopsin, IRBP, β-PDE and arrestin (22).  CRX mutations have been associated with 
both AD and AR LCA.  Fundus appearances include attenuated retinal vessels, intraretinal pigment 
deposits and areas of retinal and macular atrophy. 
The crumbs homolog 1 (CRB-1) gene produces the protein “Crumbs-like protein,” which is involved 
in photoreceptor morphogenesis.  Patients may have moderate to high hypermetropia, and although 
visual acuity is usually poor, it can rarely be as good as 0.3 logMAR.  Preservation of the para-
arteriolar RPE may be present and some patients develop a Coats’-like exudative retinopathy.  OCT 
characteristically shows significant retinal thickening with disorganisation of normal retinal 
architecture (30). 
CEP290 is a centrosomal protein and is involved in microtubule associated transport across the 
cilium (31).  Mutations lead to a rapid reduction in outer segment length and ONL thickness (32).  
CEP290 mutations are one of the most common causes of LCA, and visual acuity is usually very poor, 
despite relatively well preserved macular structure on OCT. Patients may also have olfactory defects, 
which may be helpful in identifying families with CEP290 mutations (33). 
 
The inosine monophosphate dehydrogenase 1 gene (IMPDH1) is a rare cause of LCA and is 
particularly expressed in photoreceptor inner segments and is involved with guanine synthesis, and 
converts inosine monophosphate into xanthosine monophosphate with the reduction of NAD. 
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RDH12 is present in photoreceptors and is a component of the visual cycle, catalysing the reduction 
of all-trans-retinal and 11-cis-retinal to their corresponding retinols (34).  Visual acuity may be 
moderately reduced in the early stages, but progresses to light perception or worse by the third to 
fourth decades. Night blindness is the main symptom and progressive retinal pigmentary and 
macular changes develop (35).  OCT imaging has revealed a variation in retinal thickness, with 
disorganisation of retinal architecture being a consistent finding (36).  
LRAT is localised to the membrane of the endoplastic reticulum and catalyses the synthesis of retinal 
esters.  Patients have night blindness and poor vision from early childhood, with severe early loss of 
peripheral visual field.  Fundus examination shows peripheral RPE atrophy with mild retinal pigment 
migration. 
TULP1 is a member of the Tubby-like protein family and is thought to have a role in rhodopsin 
transport from the inner to outer segment.  Affected individuals may retain reading vision in early 
years, but later can develop pigmentary retinopathy, macular atrophy and optic disc pallor. 
Visual acuity in LCA patients usually ranges from 1.0 logMAR to light perception, or even no light 
perception.  However, some cases with a visual acuity of 0.48 logMAR have been reported, usually 
with CRB1, LRAT or RPE65 mutations. Although visual acuity may initially be stable in the majority of 
LCA patients, there is generally a worsening in vision with increasing age, although there can be 
considerable variation in rate of decline between genotypes, or even within the same genotype.  
Patients with AIPL1 and RPGRIP1 mutations generally have a progressive course, whereas those with 
severe, but stable visual loss may have mutations in CEP290 or GUCY2D.  Patients with CRB1, LRAT or 
RPE65 mutations may show initial temporary improvements in visual function, but decline thereafter 
(37). 
Post-mortem retinal analysis of LCA patients has been reported in 13 adult specimens, although 
genotype information is limited.  Seven cases showed extensive loss and gliosis of the 
photoreceptor, inner retina and RPE layer, whereas a normal appearance was found in 6 eyes (22), 
providing evidence that retinal architecture can remain intact in late stages of the disease in certain 
genotypes/subjects. 
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Fig. 7 – Variability in fundus appearance of LCA patients with various genotypes – adapted from 
den Hollander et al. (22). AIPL1 – macular coloboma, optic disc pallor and retinal arteriolar 
narrowing. CEP290 – optic disc pallor and barely visible retinal vessels. CRB1 – preservation of para-
arteriolar RPE. CRX – prominent maculopathy. GUCY2D – relatively normal retinal appearance. LCA5 
– optic nerve head drusen. LRAT – mild retinal pigmentary changes. RDH12 – prominent 
pigmentation and maculopathy. RPE65 – RPE translucency with normal retinal vessels. RPGRIP1 – 
bone spicule pigment changes. TULP1 – perifoveal yellow annular ring and mild pigmentary changes. 
 
 
 
AIPL1 CEP290 CRB1 
CRX GUCY2D LCA5 
LRAT RDH12 RPE65 
RPGRIP1 TULP1 
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Symbol Locus Gene Mutation 
frequency (%) 
Gene function Clinical findings 
LCA1 17p13.1 GUCY2D 11.7 Hydrolysis cGMP Very poor vision, normal 
appearing fundus, photoaversion 
LCA2 1p31 RPE65 6 Vitamin A visual cycle Night blindness, transient visual 
improvement, relatively good 
vision in early life 
LCA3 14q31.1 SPATA7 Unknown Unknown Poor vision, retinal atrophy, 
attenuated vessels 
LCA4 17p13.1 AIPL1 5.3 Rod PDE chaperone Atrophic maculopathy, poor 
vision, night blindness 
LCA5 6q11-q16 Lebercillin 1.8 Protein transport (cilia) Severe vision loss, coloboma like 
macula 
LCA6 14q11 RPGRIP1 4.2 Protein transport (cilia) Severe vision loss, initially normal 
retinal appearance, progress to 
pigmentary retinopathy 
LCA7 19q13.3 CRX 1 Photoreceptor development Severe vision loss, infantile 
nystagmus, some dominant cases 
LCA8 1q13.3 CRB1 9.9 Müller cell photoreceptor 
interaction 
Preserved para-arteriolar RPE, 
Coats like response, thickened 
and disorganised retina on OCT 
LCA9 1p36 Unknown Unknown Unknown Single report of large Pakistani 
family 
LCA10 6q21.3 CEP290 15 Protein transport (cilia) Most common, extremely poor 
vision in most patients 
LCA11 7q31.3-q32 IMPDH1 8.3 Guanine synthesis Rare, diffuse RPE mottling, no 
pigmentary deposits 
LCA 12 1q32.3 RD3 0.1 Unknown Poor vision, atrophic macular 
lesion, rare 
LCA13 14q23.3 RDH12 2.7 Vitamin A visual cycle Fundus pigmentary fishnet or 
reticular pattern, Coats like 
response 
LCA14 4q31 LRAT 0.5 Vitamin A visual cycle Clinically like juvenile retinitis 
pigmentosa 
LCA15 6p21.3 TULP1 0.8 Protein transport (cilia) Pigmentary retinopathy, reading 
vision in early stages 
Not 
numbered 
3q13.33 IQCB1 2 Protein transport (cilia) Early ”lobular” pigmentary 
retinopathy. Renal impairment 
LCA16 2q37.1 KCNJ13 Unknown Potassium regulation Poor vision, rare 
 
Table 2 – Summary of genotype and phenotype LCA features – adapted from Chung et al. (37) 
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1.7 RPE65 genotype and phenotype 
The visual cycle is the process by which 11-cis-retinal is regenerated from all-trans-retinal after a 
photoisomerization event.  This cycle takes place in the photoreceptors and RPE, and RPE65 is a key 
isomerase in this process and is responsible for converting all-trans-retinyl ester to 11- cis-retinol.  
Without RPE65, 11-cis-retinal levels are substantially reduced and retinyl esters accumulate in the 
RPE.  
 
 The RPE65 gene was first identified in 1993 (38) and maps to 1p31.  It contains 14 coding exons, 
encoding a 65-kD protein.   Over 60 different mutations in RPE65 (http://www.retina-
international.com/sci-news/rpe65mut.htm) have been associated with a variety of overlapping 
retinal dystrophies ranging from LCA (most severe), to AR early-onset severe retinal dystrophy and 
juvenile RP, and a recently reported AD choroideremia-like phenotype (39-41).   
 
The role of RPE65 was originally considered to be the binding and mobilization of all-trans-retinyl 
esters for processing by the isomerohydrolase responsible for the critical conversion of all-trans- to 
11-cis- retinoids (42).  More recently however, it has been demonstrated that RPE65 is the 
isomerohydrolase, with RPE65 protein expression correlating linearly with isomerohydrolase activity 
(43).  RPE65 protein is highly preferentially expressed in RPE of all vertebrates, and may be 
expressed at a low level in cone photoreceptors of some species (44). The role of RPE65 in cones is 
less well established, but there is evidence that mammalian cones use an alternative retinoid 
processing cycle (in addition to the traditional one used by rods) that utilises Müller glial cells to 
regenerate chromophore for the cones (45).  This may explain why children have better cone than 
rod function in the early stages of LCA. 
 
Visual acuity in RPE65 LCA can vary considerably in the first three decades of life with reports of 
acuity ranging from 0.16 logMAR to light perception during this period (46).  However, after the third 
decade, most patients have visual acuities of 1.0 logMAR or worse with markedly constricted visual 
fields (47).  Fundus changes can vary from a normal appearance to vessel attenuation, increased 
peripheral granularity, macular pigmentation, RPE atrophy and peripheral pigment clumping – with 
changes found to increase with age (46).  The ERG is severely affected in RPE65 LCA, with typically 
undetectable rod function, but residual cone responses (47).  Retinal thickness in RPE65 LCA within 
the first three decades shows no simple relationship with age.  Retinal thickness can be within 
normal limits or show a relatively preserved central macular architecture surrounded by peripheral 
macular thinning, or demonstrate generalised retinal thinning (48).  The thickness of the ONL, seen 
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as a hyporeflective band on OCT scans, is related to the extent of photoreceptor loss. On average, 
young patients between 6 and 17 years of age show retained ONL thickness centrally and into the 
superotemporal and temporal retina, however there can be wide inter-individual differences 
irrespective of age (49).  For example, some patients in their early 20s have greater regions of 
retained photoreceptors compared to patients in the first decade of life. It is encouraging that a 
significant number of RPE65 patients have retained photoreceptor architecture, allowing the 
possibility of effective therapeutic intervention.   
 
Fundus autofluorescence (FAF) imaging measures lipofuscin accumulation in the RPE which is related 
to shed photoreceptor outer segment discs, allowing for the visualization of disease specific 
distributions of lipofuscin in the RPE which are often not visible on ophthalmoscopy.  Absent or 
minimal FAF has been reported in RPE65 LCA (50).  The transient pupillary light reflex (TPLR) is a non-
invasive method of assessing retinal function, by measuring pupil constriction to a light stimulus.  
Pupillary responses are typically sluggish in LCA, and in RPE65 patients, pupillary constriction with 
high intensity stimuli is similar to normal subjects who receive a dimmer stimulus (51).   
 
Visual pathway and cortical structure and function have also been assessed in RPE65 LCA patients 
using MRI and functional MRI (fMRI).  No significant differences have been found in optic nerve 
diameter, cortical grey and white matter, and subcortical structures compared to normal subjects.  
Visual cortex responses to dimmer light stimuli show decreased responses in RPE65 patients, 
however at brighter stimulus intensities, cortical activation is comparable to normal subjects (51).  
The TPLR and fMRI findings suggest that the visual pathway in these patients remains intact despite 
years of severe visual impairment, and that improvement in retinal function following therapy may 
result in significant visual cortical activation at lower light stimuli.    
 
The variation in phenotype amongst RPE65 mutations may be partly accounted for by the effect of 
particular gene mutations on RPE65 activity.  For example, Y144D and P363T RPE65 mutant proteins 
are less stable than wild-type RPE65 and have no detectable isomerohydrolase activity, and cause a 
severe phenotype.  Whereas, R91W, P25L and L22P show greater 11-cis retinal levels and functional 
capacity, resulting in a less severe phenotype (52). 
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1.7.1 Animal models of RPE65 deficiency 
Several animal models of RPE65 associated disease are available.  Rpe65-/- mice lack 11-cis retinal 
and 11-cis-retinyl esters, and accumulate excessive levels of all-trans retinyl esters in the RPE.  They 
have relatively normal retinal anatomy at 7 weeks, but thereafter develop slow rod degeneration 
with outer segment (OS) length starting to decrease by 15 weeks.  Thirty percent of rod 
photoreceptor nuclei are lost by 1 year, with further loss at 18-24 months (53).  In contrast, mouse 
cones show a fast rate of degeneration with severe degeneration observed by 1 month (54).   
 
Rpe65rd12 is a naturally occurring mutant model with a similar phenotype and time course of 
degeneration to Rpe65-/- mice, and no RPE65, 11-cis retinal or rhodopsin expression.  An Rpe65R91W 
knock-in mouse model has been generated which has partial expression of mutant RPE65, and 11-cis 
retinal and rhodopsin levels of approximately 10% of normal.  Outer nuclear layer thickness of 
knock-out and knock-in mice is similar with approximately 50% of the thickness of wild-type eyes, 
suggesting that a low level of rhodopsin production is not sufficient to halt rod degeneration.  
However, OS organisation is better preserved and cone degeneration is slower in the Rpe65R91W 
knock-in compared to Rpe65-/- mice (55).   
 
The Swedish Briard dog is a naturally occurring RPE65 canine animal model.  A 4-nucleotide RPE65 
deletion results in a frameshift and a premature stop codon, truncating the protein (56).  Affected 
dogs have very poor vision and severely abnormal ERG responses after 5 weeks of age.  Fundus 
appearance is normal for the first 3 years, after which there are slowly progressive changes.  These 
include large lipid-like inclusions in the RPE, OS disorganisation, and loss of photoreceptors from the 
periphery towards the centre.  The end stage of the disease involves complete degeneration of the 
peripheral retina by 5-7 years of age (57). 
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1.8 Achromatopsia 
Achromatopsia (ACHM) is a cone dysfunction syndrome inherited as an AR trait and characterised by 
an absence of functioning cone photoreceptors.  It has an incidence of approximately 1 in 30,000 
and presents in infancy with reduced vision (1.0 logMAR to 0.78 logMAR), photophobia, nystagmus 
and reduced/absent colour vision.  ACHM occurs in complete and incomplete forms, with the 
incomplete form being associated with better visual acuity and some retained colour vision.   A 
hypermetropic refractive error is common and fundus appearance is normal (Fig. 8), although retinal 
pigment epithelial abnormalities and atrophy may be present in older patients.   
Recent high-resolution retinal imaging with OCT has revealed abnormalities in outer retinal structure 
which have been suggested to progress to photoreceptor loss with advancing age, despite visual 
symptoms remaining stable in the majority of cases.  These macular abnormalities can include, 
disruption of cone inner segment (IS)/OS junction, loss of cone cells resulting in an optically empty 
cavity or hyporeflective zone (HRZ), and complete cone and RPE loss (58, 59).  In one study involving 
40 patients with an age range from 7 to 40 years, cone loss was found to be present in 42% of 
patients who were under 30 years of age, and in 95% of patients over 30 years (58).  In a second 
study of 13 patients, the presence of a HRZ was significantly associated with increasing age (59). In 
another study involving 12 patients, an intact IS/OS junction was found in two of the younger 
patients (mean age 15 years), whereas HRZ presence was found in 7 subjects with a mean age of 
32.1 years (60). These findings suggest that although patients are symptomatically stable, ACHM is a 
slowly progressive condition with loss of cone cells beginning in the second decade and progressing 
with increasing age thereafter.  In a further study of disorders of cone function, the intensity of the 
IS/OS junction has been found to be reduced in ACHM patients (n=10) who appear to have a normal 
looking structural integrity of this reflective band (61).  Furthermore, studies have indentified that 
the reflective band visible on OCT which was previously thought to originate from the IS/OS junction, 
in fact aligns with the ellipsoids of the IS (62, 63), and therefore the IS/OS junction can instead be 
referred to the IS ellipsoid (ISe) band (61). In addition, multiple ganglion cell layers with lack of 
formation of a foveal pit, consistent with foveal hypoplasia, has been found in 80% (n=40) of 
patients with ACHM (58).   
To date, mutations in 4 genes have been identified in achromatopsia, CNGA3, CNGB3, GNAT2 and 
PDE6C – all of which encode components of the cone phototransduction cascade (64-66).  CNGA3 
and CNGB3 are located at chromosome positions 2q11 and 8q21 respectively, and encode the - 
and β- subunits of the cGMP gated (CNG) cation channel in human cone photoreceptors. In the dark, 
cGMP levels are high in cone photoreceptors, therefore enabling cGMP to bind to the - and β- 
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subunits of CNG channels, resulting in them adopting an open conformation and permitting an influx 
of cations, with consequent cone depolarisation.  However, in light conditions, activated 
photopigment initiates a cascade culminating in increased cGMP phosphodiesterase activity, thereby 
lowering the concentration of cGMP in the photoreceptor which results in closure of CNG cation 
channels and consequent cone hyperpolarisation.  Over 50 different disease-causing mutations have 
been found throughout the CNGA3 gene, with the majority being missense sequence variants.   
However, four mutations (Arg277Cys, Arg283Trp, Arg436Trp and Phe547Leu) are found most 
commonly, and account for approximately 40% of all mutant CNGA3 alleles (67).  The CNGA3 gene is 
highly conserved in evolution and it appears that there is little tolerance for substitutions with 
respect to the function of the channel polypeptide.  In contrast, approximately only 15 mutations in 
the CNGB3 gene have been identified, with the vast majority being nonsense mutations.  The most 
frequent mutation is a 1 base-pair frameshift deletion 1148delC (Thr383fs), which accounts for 80% 
of CNGB3 mutant disease chromosomes (64, 68).  Approximately 25-50% of ACHM results from 
CNGA3 mutations and 40-50% from CNGB3 mutations, with less than 1% due to GNAT2 or PDE6C 
variants (69).   
 
GNAT2 comprises 8 exons and is located on chromosome 1p13, and encodes the -subunit of cone 
specific transducin. In cone cells, light activated photopigment interacts with transducin, a three 
subunit guanine nucleotide binding protein, stimulating the exchange of bound GDP for GTP. The 
cone -transducin subunit, which is bound to GTP, is then released from its β- and -subunits and 
activates cGMP phosphodiesterase by removing the inhibitory -subunits from the active site of this 
enzyme. cGMP phosphodiesterase lowers the concentration of cGMP in the photoreceptor which 
results in closure of cGMP gated cation channels.  GNAT2 mutations result in premature translation 
termination and in protein truncation, and accounts for under 1% of ACHM (65).  Residual colour 
discrimination and recordable S-cone responses have been reported in patients with GNAT2 
mutations, suggesting that S-cones may express an alternative form of -transducin (70).  
 
PDE6C encodes the cone -subunit of cGMP phosphodiesterase, which converts the second 
messenger cGMP to 5’-GMP during light exposure.  This results in closure of the cGMP-gated ion 
channel in the cone outer segment membrane, leading to hyperpolarization of the cell.  Mutations in 
PDE6C have been associated with both complete and incomplete ACHM, and AR progressive cone 
dystrophy (66). 
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Fig. 8 – Normal fundus appearance in a patient with ACHM 
 
 
Fig. 9 – Typical ERG recordings in ACHM (top) compared with normal ERG traces (bottom) - The 
rod-specific and maximal ERGs show no definite abnormality, however the cone-dependent 30Hz 
flicker and single flash photopic ERGs are undetectable 
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1.9 Gene therapy techniques 
Gene therapy involves therapeutic intervention at a genetic level.  The strategy for gene therapy of 
single-gene defects is broadly dependent on the nature of the mutation and its effect on the 
function of any protein encoded.  For loss-of-function mutations, which typically result in 
recessively-inherited disorders, the introduction of a normal version of the missing or defective gene 
can provide cells with normally functioning protein with the aim of restoring normal cell physiology.  
Mutations resulting in abnormal gain-of-function typically result in dominantly-inherited disorders.  
For these conditions the therapeutic strategy is likely to require silencing of the mutant allele. 
The eye is particularly well suited as a target organ for gene therapy.  Ocular tissues are optically 
accessible and compartmentalised, allowing microsurgical targeting and minimising potential 
systemic dissemination.  Target retinal cells are non-dividing and small in number, facilitating 
efficient transduction and sustained expression.  Relative “immune privilege” conferred by the 
blood-retinal and blood-aqueous barriers limits the impact of detrimental immune responses.  
Finally, structural and functional responses to intervention can be measured reliably using a wide 
range of sensitive imaging, psychophysical and electrophysiological techniques.  
Naked plasmid DNA has minimal ability to transfect mammalian cells and therefore successful gene 
therapy requires a vector to transfer genetic material.  The ideal vector should comfortably 
accommodate the therapeutic gene construct, efficiently transduce the target tissue, and mediate 
efficient sustained gene expression without a significant inflammatory response.  Non-viral vectors 
include liposomes, in which DNA is complexed with cationic lipids to improve cell membrane 
penetration, and nanoparticles that usually consist of a peptide or polymer base that condenses or 
encapsulates the relevant DNA.  Non-viral vectors however are typically limited by transient gene 
expression, and therefore require repeated administration (71).   
Viral vectors for ocular application are based on adenoviral, recombinant adeno-associated virus 
(rAAV) and lentivirus vectors.  The AAV genome consists of two open reading frames, rep, required 
for viral genome replication; and cap, encoding AAV structural proteins.  These are enclosed within 
two symmetric T shaped palindromic terminal sequences called inverted terminal repeats (ITRs).  
Recombinant vectors are generated by deleting the rep and cap sequences from the genome and by 
inserting the therapeutic gene of interest between the ITRs.   rAAV are non-pathogenic, single-
stranded DNA viruses that can efficiently transduce photoreceptor and RPE cells, mediating stable 
expression in the retina for several years (72, 73).  Although rAAV vectors are limited by a small 
packaging capacity (4.7 kb), recent evidence suggests that specific serotypes may be able to 
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accommodate genomes of up to 8.9 kb, considerably expanding the therapeutic potential of these 
vectors to carry larger genes such as ABCA4 (74), however subsequent studies have been unable to 
replicate this packaging capacity (75-77).  In addition, pseudotyping of AAV vectors can be 
performed which involves exchanging capsids amongst AAV serotypes (e.g. rAAV2/5 or rAAV2/8 – 
where the first number denotes the vector genome and the second the capsid) in order to improve 
transduction efficiency.  Another variable is in the use of a promoter, which is a sequence of DNA, 
upstream from the gene coding region that can have a role in targeting and controlling the location 
and degree of expression, depending on the type of promoter used. 
 
Lentiviruses are a subgroup of retroviruses, which are single stranded RNA viruses. They have a 
significantly larger packaging capacity and are capable of mediating highly efficient transduction of 
RPE.  Lentiviral vectors integrate into the host genome, with theoretical potential for insertional 
mutagenesis (78) but non-integrating versions can also lead to efficient transduction (79).  Although 
adenoviruses are able to transduce a variety of ocular tissues and have a larger packaging capacity 
than rAAV, their use as a vector is restricted because of the strong immune reaction they elicit, 
which limits the duration of gene expression (80).    
As inherited retinal dystrophies are primarily due to gene defects in photoreceptors and RPE cells, it 
is essential for vectors to successfully transduce these outer retinal structures.  Currently available 
vectors target the outer retina effectively only following subretinal administration (81).  In humans, 
subretinal delivery is usually performed using a pars-plana transvitreous approach, with injection of 
vector subretinally through a small retinotomy. Potential complications of this procedure include 
iatrogenic retinal tears and unplanned retinal detachment, intraocular haemorrhage, infection and 
cataract. 
 
Features of a condition that potentially make it suitable for ocular gene therapy include the 
following: (i) visual dysfunction that is severe enough to warrant the risks of any novel therapeutic 
intervention (ii) a relatively intact photoreceptor and RPE morphology so that treatment can have an 
effect before irreversible structural and functional loss has occurred (iii) a therapeutic gene that is 
not too large to be accommodated within an appropriate vector (iv) a sufficient number of patients 
with the disease,  and (v) a relevant pre-clinical animal model to test the therapy.  Other 
considerations include whether the aim of treatment is to improve or preserve visual function.  In 
advanced disease where significant retinal structural damage has already occurred, cell replacement 
with stem cell therapy or prosthetic retinal implants which are under development, may be better 
treatment options (82, 83).  
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1.9.1 Animal models of RPE65 gene therapy 
 
Several animal models have demonstrated the efficacy of RPE65 gene replacement therapy.   
Subretinal administration of rAAV containing RPE65 cDNA have been used to treat Rpe65-/- and 
Rpe65rd12 mice at various time points from embryonic day 14, postnatal day 14, 18 and 1-2.5, 6 and 
13 months (84-87).  Efficient RPE transduction with RPE65 protein expression was achieved at all 
treatment ages, and was detectable 7 months post-injection.  Rhodopsin and retinyl-ester levels 
were nearly normal and 11-cis retinal levels were significantly increased, with retinal morphology 
resembling a near normal appearance.  Functional improvements also occurred with significant 
improvement in ERG responses to near normal levels at 4-7 months following treatment, and 
improvements in visual acuity or visual guided behaviour.  Importantly, age-dependent effects were 
found with fewer animals who received treatment at later time points (17-26 months) 
demonstrating rescue compared to younger animals (48).  Also a dose-response effect was 
established by subretinally injecting 2-5 week old Rpe65rd12 mice with a clinical grade AAV2 vector 
(rAAV2-CB(SB)-hRPE65) and assessing ERG responses at 2 and 4 months.  A dose range from 108 to 
1010 vg/µl showed that 108 vg/µl was inefficient, 109 vg/µl showed increases in photoreceptor and 
post-receptoral sensitivity, but no increase in amplitude, whereas the 1010 vg/µl dose resulted in 
improvements in both photoreceptor and post-receptoral sensitivity and amplitude (88).   
 
Gene replacement therapy has also been successfully achieved in the Swedish Briard dog model 
using subretinal rAAV administration in a range of ages from 1 month to 4 years.  Significant 
improvements in ERG function, visual behaviour and 11-cis retinal levels were achieved, with 
functional improvement occurring as early as 2 weeks post-treatment and peak improvement 
occurring at 3 months post-treatment.  In a study of 26 eyes, significant improvement in ERG 
function was achieved in 23 eyes with restoration of near-normal sensitivity in both rod and cone 
photoreceptors, and injection at superior sites showed greater ERG responses in the area of retina 
transduced, than at inferior sites (89).  A dose-response effect has also been found in dogs who 
received AAV2 therapy with a cytomegalovirus/chicken β-actin promoter, with significantly more 
eyes showing improvement who received a higher dose (15x1010 vg/µl) compared to eyes receiving a 
lower dose (4.5x1010 vg/µl) (90).  Behavioural studies in treated dogs have shown improvements in 
TPLR from approximately 0.5 to 4 log units, implying that improvements in retinal function are being 
transmitted further along the visual pathway.  Evaluation of visual cortical activity with fMRI has 
shown with significant improvements in activity in the lateral gyrus region in treated dogs, to levels 
of activity approaching that of wildtype controls (51).   The immunological effects and biodistribution 
following subretinal rAAV-RPE65 defects have shown an increase in neutralising antibodies to AAV2 
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during the first 12 months (91), but no significant increase in the humoral response to the AAV2 
capsid at 3 months post-injection, and studies of brain kidney and bone marrow did not reveal 
extraocular expression of RPE65.  Minor surgical complications included mild/moderate conjunctival 
injection, transient vitritis and lens opacity development (90).  Similar to the mouse models, an age-
dependent effect has been reported in dogs with functional improvement being greater in dogs 
treated at 8 versus 30 months of age (92).  Long term effects of treatment have been studied and 
improvements in ERG function have been maintained at 3 years following injection (87). 
 
Safety effects of gene therapy have been assessed in non-human primates.  Subretinal injection of 
rAAV2 carrying green fluorescent protein (EGFP) in monkeys, revealed no long term toxicity and 
stable and efficient EGFP transgene expression was found localised to retinal cells for over 1 year  
(93).  In another study, subretinal rAAV2-RPE65 injection (at the highest dose of 4.5x1012vg/µl)  in 
monkeys showed minimal or no systemic dissemination of vector sequences at 3 months post-
injection, and no vector genomes were detected in the gonads of male or female subjects.  No 
toxicity effects were found with ERG testing compared to the untreated eye, however minor 
anatomical differences were noted at the fovea including subretinal or intraretinal pigmentary 
disturbances (94). 
 
The safety and efficacy results from these animal studies helped lead the way towards the 
application of rAAV2-RPE65 gene therapy in humans. 
 
 
1.9.2 Animal models of gene therapy for ACHM 
Several animal models have been used to demonstrate that AAV mediated gene therapy can be 
effective in restoring cone function in ACHM.  Gnat2cpfl3 homozygous mice (which have a missense 
mutation in cone -transducin) at ages day P27 and P29, were given a subretinal injection of AAV5 
carrying wild type mouse Gnat2 cDNA.  Cone-specific ERG responses were restored to within the 
normal amplitude range and visual acuity was restored to normal levels when assessed with 
optomotor behavioural testing.  To investigate the effect of treatment in older mice, 9 month old 
Gnat2cpfl3 mice were injected and ERG rescue 1 month later remained feasible, and in one case b-
wave amplitude reached wild type levels (95). 
A cnga3-/- mouse model has received subretinal injection of AAV carrying the cnga3 cDNA at day P12 
to P14, and resulted in restoration of cone ERG responses at 10 weeks post treatment.  Functional 
improvements in visually guided behaviour were also found utilising a water maze under photopic 
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light conditions, with red and green cues.  Immunohistochemistry showed that cnga3 protein was 
present specifically in cones and localised throughout the cone photoreceptor.  In addition, cnga3 
expression lowered cGMP levels, delaying cone death and reducing the inflammatory response of 
Müller glia cells that typically occurs in retinal degeneration (96).  In another model using naturally 
occurring cpfl5 mice (who have a missense mutation in exon 5 of the cnga3 gene) AAV mediated 
Cnga3 delivery at day P14 led to restored and stable light adapted ERG responses for at least 2 
months after treatment (97). 
In a cngb3-/- mouse model, subretinal injection of AAV2/8 containing the human cngb3 transgene 
gene driven by the human cone arrestin promoter, resulted in both age-dependent and long term 
restoration of visual function.  Mice were treated at day P6, P15, P30, P90 and P180 and underwent 
ERG testing, visual acuity testing and immunohistochemistry.  ERG recordings showed that mice 
treated at P15 and P30 achieved near normal restoration (>90% of wild-type level) that persisted for 
at least up to 270 days post injection.  However, treatment at P180 only resulted in 60-70% of wild 
type restoration.  Further evidence of an age-dependent effect, was that mice treated at P30 
achieved normal visual acuity levels, compared to P180 mice that showed no significant difference in 
visual acuity between treated and untreated eyes.  Improved cone survival was found in treated 
Cngb3-/- eyes, with improvement in cone density, expression of cone proteins and improved 
structure of cone outer segments (98). 
Furthermore, successful restoration of cone function has been achieved in two canine models of 
CNGB3 mutations – a missense mutation in exon 6 (CNGB3m/m) and a deletion of the entire CNGB3 
gene (CNGB3-/-).  An age-dependent treatment response was found with only 1 of 3 eyes treated 
after 54 weeks of age achieved clear restoration of cone ERG function, compared to 11 out of 14 
eyes that received treatment before 28 weeks.  Improvements in photopic vision were also found 
when assessed by observing the ability of the dogs to manoeuvre around an obstacle course (99). 
These studies have provided encouraging evidence that gene therapy for ACHM can lead to 
improvements in cone function and structure.  In keeping with many other animal models of 
inherited retinal disease, efficacy has been shown to be age-dependent; this may also prove to be a 
limiting factor in human clinical trials of achromatopsia gene replacement therapy. 
In addition, to optimise the success of a human clinical trial of gene therapy for ACHM, a greater 
understanding of the relationship between retinal structure and function amongst patients of 
different ages and genotypes will be important to help identify patients who are most likely to 
benefit from intervention, and at what time-point. 
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1.10 Clinical assessments of retinal function and structure 
There are various techniques available for investigating visual and retinal function, and retinal 
structure.  These allow an assessment of current disease status and can help identify patients who 
are potentially most suitable for therapeutic intervention.  They also enable monitoring of disease 
progression and can help detect changes in function following therapy. 
Visual acuity 
Best-corrected visual acuity (VA) is measured by the smallest letter size a person can read from an acuity 
chart with any refractive error corrected. Although there are a wide range of VA charts available, the 
Early Treatment Diabetic Retinopathy Study (ETDRS) chart is commonly used in research studies, and has 
several advantages.  The ETDRS chart is standardised with equal numbers of letters per row; equal 
spacing of letters on a row; equal spacing between rows; rows are balanced for difficulty; and the chart 
provides accurate conversion for Snellen and Logarithm of Minimum Angle of Resolution (logMAR) 
scoring.  Testing distance from the chart is determined by the participant’s ability to identify the first line 
of letters correctly.  Each eye is measured individually, whilst the fellow eye is occluded.   
Contrast sensitivity 
Contrast sensitivity (CS) is effectively a measure of the eye’s ability to distinguish shades of grey, and 
can be assessed using the Pelli-Robson (P-R) contrast sensitivity chart. The P-R chart comprises 16 
triplets of letters arranged in 8 rows of two triplets, each subtending 2.8 deg at the test distance of 1 
metre.  The three letters within each triplet have constant contrast, whereas the contrast across 
triplets, reading from left to right, and continuing on successive lines, decreases by a constant factor.  
The final triplet at which the patient can read 2 of 3 letters correctly determines the log contrast 
sensitivity; with the normal range being from 1.68 logCS to 1.84 logCS (100). 
Reading acuity 
The purpose of taking reading measurements is to evaluate the participant’s ability to perform 
reading as an everyday task and provide a measure of near acuity; with the MN-Read card being 
commonly used. The MN-Read card comprises 19 sentences of high contrast proportionally spaced 
text, each containing 60 characters printed as three lines with justified margins.  Words used are of a 
high frequency in 2nd and 3rd grade USA reading material.  The sentences have been calibrated to 
give the correct logMAR sizes, each being 0.1 logMAR units smaller than the previous sentence.   
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The participant reads the chart at a distance of 40 cm (or 25cm if the visual acuity is worse than 0.76 
LogMAR), whilst the researcher records the smallest text size participants can read (reading acuity). 
Fundus photography 
High-resolution digital colour fundus photography is helpful both in the diagnosis of retinal disease, 
and documenting and monitoring progression of retinal degeneration.  It is also useful when 
comparing to other forms of retinal imaging. 
Optical coherence tomography 
Optical coherence tomography (OCT) is a non-invasive imaging modality that enables in vivo cross-
sectional visualization of the retinal structure, and has become increasingly used in the diagnosis and 
monitoring of a range of retinal conditions.  OCT is based on an optical technique known as 
Michelson low coherence interferometry, which measures the echo delay and intensity of back 
reflected or backscattered infrared light (approximately 800 nm) from internal tissue microstructure, 
to achieve two- or three-dimensional cross-sectional tomographic images of optical reflectivity.  The 
principle of OCT imaging is analogous to B-scan ultrasonography, except that OCT measures light 
rather than acoustic waves from the tissue boundaries. 
Initial OCT images were acquired in a “time domain” fashion which acquire approximately 400 A-
scans per second using 6 radial slices oriented 30 degrees apart.  However, as the slices are 30 
degrees apart it is possible to miss pathology between the slices.   More recently, “Spectral domain” 
OCT (SDOCT) technology has been introduced, which scans approximately 20,000-40,000 A-scans 
per second. This increased scan rate and number reduces the likelihood of motion artefact, 
enhances the resolution and decreases the chance of missing lesions.  Whereas most time domain 
OCTs are accurate to 10-15 microns, newer spectral domain devices may approach 3 micron 
resolution and perform a series of horizontal scans in a predetermined sized area, rather than 6 
radial slices.  
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Electrophysiological testing 
Electrophysiological assessment of the retina is useful in establishing the level of any abnormality 
(e.g. photoreceptor/RPE or inner retina) and also the extent, in terms of macular and or/peripheral 
dysfunction. The standard electrophysiological tests that are performed include the electro-
oculogram (EOG), a full-field electroretinogram (ERG) and pattern ERG (PERG).   There are 
established protocols for each of these assessments, defined by the International Society for Clinical 
Electrophysiology of Vision (101). 
 
The ERG is the massed electrical response of the retina and allows assessment of generalised retinal 
function under photopic and scotopic conditions, using a Ganzfeld bowl flash stimulus.  Standard 
ERG traces include (1) Dark-adapted 0.01 ERG (formerly “rod-specific response”); (2) Dark-adapted 
3.0 ERG (formerly “maximal mixed rod-cone response”); (3) Dark-adapted 3.0 oscillatory potentials 
(formerly “oscillatory potentials”); (4) Light-adapted 3.0 ERG (formerly “single-flash cone response”) 
and (5) Light-adapted 3.0 flicker (formerly “30 Hz flicker”).   
 
The rod-specific ERG b-wave is generated at the level of the inner nuclear layer.  The initial 10-12 ms 
of the a-wave of the maximal response relates to photoreceptor hyperpolarisation, and is the best 
measure of photoreceptor function.  The slope of the linear portion of the a-wave can be related to 
the kinetics of phototransduction.  The b-wave of the maximal ERG response arises in the mid-retina, 
principally from the rod ON-bipolar cells and thus defines function that is post-phototransduction or 
post-receptoral.  Photopic (single flash) and 30 Hz flicker allow assessment of cone function.  There 
are mid-retinal contributions to both the a- and b-waves of the photopic (single flash) ERG response, 
but also a photoreceptor contribution to the photopic a-wave.   
 
The PERG is usually elicited using high contrast checkerboard reversal and mainly reflects central 
retinal function.  There are two major components: the positive P50 - which is driven by macular 
photoreceptors and can be used as an objective index of macular function, and the N95 – which is 
considered to arise in the spiking activity of the retinal ganglion cells. 
 
The EOG utilises the standing potential difference between the back of the eye and the electro-
positive cornea.  It is a mass response of the whole retina and is generated across the RPE.  The EOG 
is assessed by measuring constant eye movements under progressive dark then light adaptation.  
There is a “dark trough” after 12-15 minutes dark adaptation and a “light peak” after 7-10 minutes 
light adaptation.  The ratio between the light peak and dark trough is expressed as a percentage, and 
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is the commonly used parameter. The EOG allows assessment of the photoreceptor/RPE interface 
and its generation depends on the integrity of the photoreceptors.  A reduced EOG is generally 
accompanied by a reduction in the full-field ERG, unless dysfunction is confined to the RPE. 
 
Retinal dystrophies may be classified on the basis of the associated electrophysiological 
abnormalities.  Patients with generalised retinal dysfunction and severe ERG abnormalities can have 
normal PERGs if the macula is spared.  In contrast, patients with disease confined to the macula have 
normal ERGs, but the PERG P50 may be profoundly abnormal.  
 
 
 
Fig. 10 – Diagram of the five basic ERG responses -  adapted from Marmor et al.(101). Large arrows 
indicate stimulus flash. Dotted arrows illustrate how to measure time to peak (t, implicit time), a-
wave amplitude and b-wave amplitude.  
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Microperimetry 
Microperimetry is an assessment method that can reliably measure retinal sensitivity to light at 
specific locations across the retina.  Subjects fixate on a central target while specific retinal locations 
are presented repeatedly with a Goldmann size I to V stimulus for a duration of typically 200ms.  A 
commonly used microperimeter is the Nidek MP1 microperimeter (NAVIS software version 1.7.1, 
Nidek Technologies, Padova, Italy).  The MP-1 initially takes an infrared photograph and the software 
package allows the operator to select a biological landmark of high reflectivity under infrared e.g. a 
bifurcation of a retinal vessel.  This image is then digitally registered and matched with the 
corresponding area on the live video of the patient’s retina.    An active eye tracking system corrects 
for fixation errors to ensure accurate stimulus projection in relation to retinal landmarks. 
 
Dark-adapted perimetry 
Dark-adapted perimetry using a modified Humphrey Visual Field Analyzer is an established method 
for quantifying rod and cone sensitivity (102).  The standard technique uses a 30-2 Full Threshold 
Test with optical filters to isolate a narrow range of wavelengths and differentiate between rod and 
cone function; with near 500 nanometres used to probe rod sensitivity.  Measurements are made in 
the fully dark adapted eye with a Size III or V target.  The test is fully automated, thereby markedly 
reducing potential experimenter bias and the subject’s eye position can be continually monitored by 
an infrared camera. 
Visual mobility testing 
Visual mobility testing provides a quantitative assessment of a subjects’ ability to navigate in a “real 
life” scenario.  One such testing environment is the Pedestrian Accessibility & Movement 
Environment Laboratory (PAMELA) facility of UCL.  PAMELA is a unique mobility research facility (in a 
specially designed, converted warehouse building) that incorporates a sophisticated set of 
monitoring and data collection systems including starlight video cameras, laser scanners which can 
locate objects in the laboratory within 1-2cm, eye tracking systems and heart rate monitors.  Visual 
mobility is tested by subjects negotiating a maze with moveable barriers and the entire platform 
area is illuminated from overhead to calibrated light levels ranging from 240 lux (moderate office 
lighting) to 4 lux (UK night time pedestrian lighting standard). Subjects are positioned at one end of 
the maze and instructed to walk through at a normal comfortable pace without touching the 
barriers.  An experimenter follows along just behind to ensure the subject’s safety. Total travel time 
is recorded with a stopwatch along with mobility errors (touching a barrier, loss of orientation).  
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2.1 RPE65 Trial 
Aim of trial 
The main objective of the trial is to determine the safety and efficacy of subretinal administration of 
a recombinant adeno-associated viral vector (rAAV 2/2.hRPE65p.hRPE65) at two different dosage 
levels in 12 subjects with autosomal recessive severe early-onset retinal degeneration (LCA) due to 
mutations in RPE65. 
This study was approved by the UK Gene Therapy Advisory Committee, the Medicines and 
Health Products Regulatory Authority, the Moorfields Research Governance Committee, and the 
local research ethics committee.  All patients gave written informed consent and the study was 
conducted in compliance with Good Clinical Practice guidelines according to the European Clinical 
Trials Directive (Directive 2001 EU/20/EC) and the Declaration of Helsinki.   
The decision to include 12 patients in this trial was determined after consideration of the likelihood 
of recruiting patients, and the practical and economical aspects in terms of resources available to 
provide adequate assessments and support for this trial. 
This study involves 2 centres: (1) UCL Institute of Ophthalmology, London, (2) Moorfields Eye 
Hospital, London. 
 
2.1.1 Inclusion criteria: 
The inclusion criteria for this trial were subjects with: 
1. Severe early-onset retinal dystrophy (LCA) 
2. Homozygous or compound heterozygous for a missense or null mutation(s) in RPE65 
3. Aged 5 to 30 years 
4. Able to give informed consent or assent, with or without the guidance of their 
parent/guardian where appropriate 
 
2.1.2 Exclusion criteria: 
The exclusion criteria for this trial were: 
1. Subjects having contraindications for transient immune-suppression (hypertension, diabetes 
mellitus, tuberculosis, renal impairment, immunocompromise, osteoporosis, gastric 
ulceration, severe affective disorder 
2. Pregnant or lactating women 
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2.1.3 Consent 
All patients underwent full informed consent with the following issues discussed in particular: 
1. The potential for no benefit following treatment 
2. The potential for loss of vision due to the following: 
a. Complications of surgery, including retinal detachment and infection 
b. Inflammation due to immune responses to vector or RPE65 protein 
3. The theoretical potential for malignancy, spread of vector to other organs and germline 
transmission 
4. The nature and duration of follow-up, including the need for long-term follow up of subjects 
5. The decision regarding which of their two eyes was to receive the intervention was 
determined by the relative degrees of visual impairment and retinal degeneration. The 
potential benefits and risks of intervention in each eye were discussed with each patient 
who was fully involved in this decision as part of the consent process. 
 
2.1.4 Preoperative procedure 
Subjects were screened to ensure there were no contra-indications for transient immune 
suppression.  A detailed assessment of visual function and imaging was performed on both eyes 
preoperatively as outlined in schedule of investigations (see 2.1.8).  The eye with worse visual 
impairment was selected to undergo treatment. 
Blood was sampled in order to assess baseline levels of circulating antibodies against AAV2 and 
RPE65 so that following intervention, immunological responses to vector capsid and transgene 
product might be determined.  
For prophylaxis against potential intraocular immune responses to the vector, subjects were 
prescribed a course of oral prednisolone commencing at a dose of 0.5 mg/kg one week prior to 
surgery; 1mg/kg for the first week following vector administration, 0.5mg/kg for the second week, 
0.25mg/kg for the third week and 0.125/kg for the fourth week.  
2.1.5 Recombinant adeno-associated virus details 
The virus used to transfer the RPE65 gene was the tgAAG76 vector - a recombinant adeno-
associated virus vector of serotype 2. The vector contains the human RPE65 coding sequence driven 
by a 1400-bp fragment of the human RPE65 promoter and terminated by the bovine growth 
hormone polyadenylation site.  The vector was produced by Targeted Genetics Corporation 
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according to Good Manufacturing Practice guidelines with the use of a B50 packaging cell line, an 
adenovirus–adeno associated virus hybrid shuttle vector containing the tgAAG76 vector genome, 
and an adenovirus 5 helper virus. The vector was filled in a buffered saline solution at a titre of 
1×1011 vector particles per ml for subjects 1 to 4, and at a titre of 1×1012 vector particles per ml for 
subjects 5 to 12, and frozen in 1ml aliquots at −70°C. 
 
2.1.6 Technique for surgical delivery of vector 
The recombinant vector was delivered in the form of a suspension of viral vector particles injected 
intraocularly (subretinally) under direct observation using an operating microscope. The procedure 
involved a standard 3-port pars plana vitrectomy with a moderate anterior core vitrectomy  
performed before inducing (when possible) a posterior vitreous detachment, by aspiration over the 
optic nerve head.  
Intraocular administration of the viral vector suspension (rAAV2/2-hRPE65p-hRPE65) was performed 
using a de-Juan 41-gauge cannula attached to a 1 ml syringe.  The plunger of this syringe is driven by 
a mechanised device by depression of a foot pedal.  The 41-gauge cannula was advanced through 
the retina at a site pre-determined in each subject according to the area of retina to be targeted.  
Under direct visualisation the vector suspension was injected mechanically under the neurosensory 
retina causing a localised retinal detachment with a self-sealing non-expanding retinotomy.  The 
injection of vector suspension was preceded by injection of a small volume of Ringer’s solution (0.1 
to 0.5 ml) to establish a “bleb”, facilitating targeted delivery of vector suspension to the subretinal 
space and minimising possible exposure of the choroid and vitreous cavity to vector. A sample of 
uninjected vector suspension was retained for subsequent analysis of bioactivity.  
Closure of all sclerotomies was completed with 7/0 vicryl sutures. Standard doses of cefuroxime 
antibiotic and betamethasone were administered subconjunctivally as prophylaxis against 
postoperative infection and inflammation respectively.  
2.1.7 Early post operative management 
The operated eye was examined 2 hours after surgery and any intraocular pressure of greater than 
30 mmHg was managed using appropriate ocular antihypertensive therapy.  
A standard post-vitrectomy treatment regimen of topical antibiotic (chloramphenicol 0.5% qds for 7 
days), steroid (dexamethasone 0.1% qds for 4 weeks) was commenced to minimise inflammation 
and protect against infection postoperatively.  Subjects were maintained on oral prednisolone for 4 
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weeks following administration of vector suspension as described above.  The possible development 
of steroid-induced adverse effects was monitored regularly - in particular, blood pressure, blood 
glucose, renal function and liver function tests.   
Safety assessments were performed at 1 day, 2 days, 4 days, 7 days, 2 weeks, 3 weeks, 4 weeks and 
6 weeks following treatment.  These included visual acuity, ocular examination, OCT, fundus 
photography, systemic review, temperature and blood pressure recording, and serology including 
immune status. 
2.1.8 Assessments of visual function and immune status 
Detailed phenotypic assessments were performed at intervals of 2 months for 12 months, then 
annually until 3 years following administration of the vector.  These assessments were scheduled 
over a period of up to 4 days for each time point. Assessments are listed below. Visual mobility was 
assessed at baseline and at 6 months following treatment. 
List of assessments subjects underwent: 
1. Best corrected visual acuity (BCVA) 
2. Contrast sensitivity (CS) 
3. Reading acuity 
4. Microperimetry 
5. Dark-adapted perimetry 
6. Visual mobility 
7. Clinical examination 
8. Serology/immune assays 
9. Fundus photography 
10. Optical coherence tomography (OCT) 
11. Electrophysiology 
12. Visual mobility 
 
2.1.9 Endpoints 
The endpoint for toxicity for each subject is a Grade III adverse event, defined as loss of visual acuity 
by 15 or more ETDRS letters, or severe unresponsive intraocular inflammation. 
The endpoint for efficacy for each subject is defined as any improvement in visual (rod- or cone- 
derived) function as determined by an array of psychophysical and electrophysiological techniques, 
that is greater that the test-retest variation for each test. 
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2.1.10 Methodology of assessments 
Visual acuity, contrast sensitivity and reading acuity assessments 
Subjects underwent best corrected visual acuity assessment using the ETDRS chart at a distance of 
4m or less, according to their visual ability, and logMAR acuity was recorded, with a change in visual 
acuity of more than 0.3 logMAR considered significant (103). The Pelli-Robson chart was used to 
measure contrast sensitivity at a distance of 1m with logCS sensitivity recorded.  A change in 
contrast sensitivity of more than 0.2 logCS was considered clinically significant (104).  The MN Read 
acuity chart was used to measure reading acuity in all subjects at 25cm (or 40cm if the visual acuity 
was better than 0.78 LogMAR), and a change of more than 0.3 logMAR was considered as significant 
(105).   
Immunological assays (undertaken by Dr Susie Barker) 
1. Circulating neutralising antibodies against AAV2:  Serum was assayed for the ability to block the 
transduction of 293T cells with AAV2-GFP.  Serum was serially diluted in 96 well plates using DMEM.  
AAV2-GFP was added to each well and plates were incubated at 37°C for 1 h before addition to 293T 
cells in triplicate.  Baseline serum for each subject was assayed alongside each post-gene therapy 
sample. Green cells were counted in the test wells after 48 h and compared to the number of green 
cells in the baseline serum sample, and to the no serum positive control sample.  The neutralising 
antibody (NAb) titre was expressed as the serum dilution that resulted in 50% inhibition of 
transduction of 293T cells by AAV2.GFP. 
2. Serum ELISA to detect circulating levels of IgA, IgG and IgM against rRPE65:  Microtitre plates 
were coated overnight with 0.5μg/ml rRPE65 in PBS then blocked with 10% goat in PBS.  Serum 
dilutions in PBS/1%BSA were added to wells (replicates of 4) and incubated for 2 h.  Plates were 
incubated with anti-human IgA, IgG, IgM-HRP, then developed with 3,3’,5,5’-tetramethylbenzydine 
(TMB) substrate. Serum test samples were always compared to the baseline serum that was 
obtained pre-gene therapy and run alongside in every assay.   
3. Serum ELISA to detect circulating levels of IgA, IgG and IgM against AAV2:  Microtitre plates were 
coated overnight with 108 vp/well AAV2 in carbonate buffer then blocked with 1% BSA, 5% sucrose 
in PBS-T. Serum dilutions in PBS/1% dried milk were added to wells (replicates of 4) and incubated 
for 2 h.  Plates were incubated with anti-human IgA, IgG, IgM-HRP, then developed with TMB 
substrate. Serum test samples were always compared to the baseline serum that was obtained pre-
gene therapy and run alongside in every assay.   
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4. ELISpot assay to detect secretion of the Th1 cytokine IFNγ in response to co-culture with AAV2:  
PVDF plates were coated with anti-IFNγ antibody (Mabtech, Sweden) and blocked with FCS.   PBMC 
were resuspended in serum-free media (Cellular Technologies Limited, Germany) and 2.5 x 105 cells 
added per well.  Positive controls contained anti-CD3 (Mabtech, Sweden) and negative controls were 
incubated in media only. Triplicate test wells contained 107 particles rAAV2/2.hRPE65p.hRPE65.  
Plates were incubated at 37°C for 48 h.  Plates were developed using an avidin-alkaline phosphatase 
detection system following a biotinylated detection antibody (Mabtech, Sweden).  The data shows 
the average spots per well of triplicate test well.   Test wells with more than double the number of 
spots in the negative controls and more than 15 spots were considered to be a positive response 
against antigen.   
Microperimetry 
Microperimetry was performed using a Nidek MP1 microperimeter (NAVIS software version 1.7.1, 
Nidek Technologies, Padova, Italy).  Following 10 minutes of dark adaptation, a white fixation cross 
(31.8 cd/m2) was displayed on a dim background (1.27 cd/m2).  Goldman V stimuli of 200 ms 
duration and a maximum luminance of 127 cd/m2 were presented with a 4-2 adaptive staircase 
threshold strategy.  All testing followed a standardised, detailed protocol, with controlled room 
lighting, dark adaptation period and a fixed sequence of test patterns.  The test is fully automated so 
there is little opportunity for experimenter bias. The subject’s eye position was continually 
monitored by an infrared camera and the microperimeter tracks the eye movements to compensate 
for shifts in the direction of gaze. Reliability parameters were determined for each test including 
fixation losses, false negative and false positive responses.  Test reliability was assessed by projecting 
a light onto a known blind spot (the optic nerve head); positive responses to the light indicated poor 
reliability.  The mean sensitivity in dB was recorded per spot. 
 
Dark-adapted perimetry 
In dark-adapted conditions using a short wave length stimulus, sensitivities were measured at 76 
locations in the central visual field using a modified Humphrey perimeter. Measurements were 
made between 60 and 240 minutes dark adaptation using Goldman V stimuli of 200 ms duration.  All 
testing followed a standardised, detailed protocol, with controlled room lighting, dark-adaptation 
period and a fixed sequence of test patterns. The test is fully automated so there is little opportunity 
for experimenter bias.  The subject’s eye position was continually monitored by an infrared camera, 
therefore allowing fixation to be monitored and controlled for the duration of the test. Reliability 
parameters were determined for each test including fixation losses, false negative and false positive 
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responses.  Test reliability was assessed by projecting a light onto a known blind spot (the optic 
nerve head); positive responses to the light indicate poor reliability. 
Analysis of dark adapted perimetry was performed using Progressor Software (106, 107).  This 
program applies linear regression analysis to each of the individual test locations to determine 
whether there is statistically significant progression in sensitivity in that area.  The number of 
locations with a significant (p<0.05) change in sensitivity and also the mean sensitivity of the 
locations with a significant sensitivity change can be identified with Progressor.   Each measurement 
is depicted by a bar; the lengths of the bars represent sensitivity, with the long bars showing loss of 
sensitivity and the short bars showing normal sensitivity.  Yellow indicates a decline in sensitivity 
that is not significant, red indicates a decline that is significant (P<0.05), and green indicates an 
improvement that is significant (P<0.05). 
 
Assessment of visual mobility 
Visual mobility was tested with a 10.8m x 7.2m raised platform with concrete paving stones that 
were configured to simulate an outdoor pavement.  Subjects negotiated a 13m long maze with 8 
moveable barriers (1.8m x 1.2m) painted in colours matching light or dark blue denim, and the entire 
platform area was illuminated from overhead to calibrated light levels ranging from 240 lux 
(moderate office lighting) to 2 lux (less than UK night time pedestrian lighting standard). The subject 
was positioned at one end of the maze and instructed to walk through at a normal comfortable pace 
without touching the barriers.  The experimenter followed along just behind to ensure the subject’s 
safety. Total travel was recorded with a stopwatch along with mobility errors (touching a barrier, 
loss of orientation). The barriers were randomly re-positioned before each run and the subject was 
given 15 minutes to adapt to changes in illumination levels. 
 
OCT imaging 
Subjects underwent dilated SDOCT imaging (Heidelberg Engineering, Germany) with line or volume 
scans at the horizontal meridian.  The volume acquisition protocol consisted of 49-B scans (averaging 
12 frames per B-scan and 124 micron space between scans) covering an area of 20 by 20, with the 
Automatic Real Time (ART) eye tracking software enabled.  If a subject’s fixation ability did not allow 
capture of these images, the volume scans were obtained with the ART feature disengaged.  Foveal 
thickness was determined using the automated retinal thickness measurements between the inner 
limiting membrane (ILM) and the inner border of the line of back-reflection indicating the RPE.  The 
status of the external limiting membrane (ELM) and IS/OS junction were judged for any 
discontinuity. 
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Electrophysiological testing 
All subjects underwent electrophysiological evaluation including full-field, pattern, and 
multifocal electroretinography performed to incorporate the standards and guidelines of the 
International Society for Clinical Electrophysiology of Vision (101).  
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2.2 Retinal structure and function in Achromatopsia: implications for gene 
therapy 
The aims of this study are to establish a panel of well phenotyped patients with ACHM, by 
quantatively and qualatively assessing disease status, investigating the relationship between retinal 
structure and function and correlating phenotypic findings with age and genotype. This information 
will have implications for a planned gene therapy trial in terms of patient selection, identifying time-
points to intervene, and in determining efficacy.  
40 patients with a clinical diagnosis of ACHM were included in this study. The number of subjects 
was decided upon by an estimation of the likelihood of recruiting patients and performing adequate 
assessments in study time period available. Patients were identified from a genetic database of 
inherited retinal conditions at Moorfields Eye Hospital. The diagnosis of ACHM was based on 
patients having a phenotype consistent with ACHM, which included onset from birth/early infancy, 
reduced visual acuity, photophobia, absent/markedly reduced colour vision, nystagmus in infancy, 
and absent cone ERG responses, with normal rod function.     
All patients underwent a clinical history and complete ocular examination, best-corrected ETDRS 
visual acuity, reading and contrast sensitivity assessment, colour fundus photography, spectral 
domain OCT (SDOCT), microperimetry and colour vision testing. If not previously performed, patients 
underwent full-field ERG and molecular genetic screening of CNGA3 and CNGB3 for disease-causing 
variants.   
The study received approval from the local ethics board and was performed in accordance with the 
tenets of the Declaration of Helsinki, with informed consent obtained from all patients after 
explanation of the nature of the study.   
2.2.1 Visual acuity 
All subjects underwent visual acuity assessment using the back-illuminated Early Treatment of 
Diabetic Retinopathy Study (ETDRS) chart. The chart surface had a luminance of 100-125 cd/m2 and 
the test was undertaken at a distance of 4m. If prescribed, the participant used their distance 
spectacles. Each eye was initially measured individually, followed by assessment with both eyes 
open. A different chart was used for each patient’s right and left eyes and for both eyes together.  
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2.2.2 Contrast sensitivity 
The Pelli-Robson chart was used to measure contrast sensitivity in all subjects.  Each eye was tested 
individually at a distance of 1m.  
2.2.3 Reading acuity 
The MN Read acuity chart was used to measure reading acuity in all subjects.  The chart was read at 
25cm (or 40cm if the visual acuity was better than 0.78 logMAR).   
2.2.4 Colour vision tests 
The colour vision of all subjects was assessed using both the Ishihara and Hardy Rand and Rittler 
(HRR) pseudoisochromatic plates. With the Ishihara test, if the subject was able to read the first test 
plate they were then asked to state the numbers on plates 2-25 without more than three seconds 
delay. If the participant was unable to read numbers, plates 26-38 were used and subjects asked to 
trace the winding paths. The HRR test comprises of 30 plates which contain one or two coloured 
symbols. Subjects were asked how many they could see and what symbol they were. Both sets of 
plates were held at 75cm from the subject and tilted so that the plane of the paper was at 90 
degrees to the line of vision. 
2.2.5 Fundus examination 
On the basis of their fundus appearance on colour fundus photography, each subject was 
assigned into one of 3 categories (i) no RPE disturbance, (ii) RPE disturbance or (iii) atrophy 
(58). Images were independently assessed by two observers (VS and MM) and agreement 
on grading was found in 100% of cases. 
2.2.6 Microperimetry 
Microperimetry was performed on both eyes of all patients using the MP-1 microperimeter (Nidek 
technologies, Padova, Italy).  Test-retest variability was probed by all patients having 2 tests 
undertaken on each eye. A customized test grid of 44 retinal locations with an eight degree radius 
was used to cover the macular and paramacular region.  The testing was conducted in a darkened 
room and all subjects underwent training at the beginning of MP testing, allowing familiarisation and 
practice with the correct operation of the response trigger and the stimulus target. This was 
followed immediately by the actual test. All tests were performed after pupil dilatation with 
tropicamide 1% and phenylephrine 2.5%. Patching of the non-tested eye was performed.   
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Subjects were instructed to fixate on a 2-degree cross fixation target and background illuminance 
was set within the mesopic range at 1.27cd/m2.  A Goldmann size III stimulus with an area of 4mm2 
and 200ms duration was used.  A 4-2 testing strategy was employed, with the intensity of the 
stimulus reduced in 4dB steps until it is no longer recognised by the subject.  The threshold is then 
crossed a second time by increasing the stimulus intensity by 2dB steps until it is detected once 
again.  False positive errors were tested for by measuring responses to stimuli projected into the 
blind spot at 30 second intervals.  Fixation stability was assessed using the bivariate contour ellipse 
area (BCEA) which represents an area in degrees where 68% of fixation points are located (108), and 
this value can be accessed directly using the Nidek software 
Repeat testing was performed on all subjects using the “follow-up” test option, which requires 
alignment of specific retinal landmarks at each subsequent test, to ensure similar location of stimuli 
projection. 
2.2.7 OCT Imaging 
Subjects underwent dilated SDOCT imaging (Heidelberg Engineering, Germany) with line or volume 
scans at horizontal the meridian.  The volume acquisition protocol consisted of 49-B scans (averaging 
12 frames per B-scan , and124 micron space between scans) covering an area of 20 by 20, with the 
Automatic Real Time (ART) eye tracking software enabled.  If a subject’s fixation ability did not allow 
capture of these images, the volume scans were obtained with the ART feature disengaged. Images 
were assessed and graded into 5 categories: (i) continuous inner segment ellipsoid (ISe) at the fovea; 
(ii) ISe disruption at fovea; (iii) ISe absence at fovea;(iv) hyporeflective zone (HRZ) presence; and (v) 
outer retinal atrophy including RPE loss (58). The presence of foveal hypoplasia (defined as the 
persistence of one or more inner retinal layers (outer plexiform layer, inner nuclear layer, inner 
plexiform layer or ganglion cell layer) was also assessed. Images were independently assessed by 2 
observers (VS and JC) who agreed on OCT categorisation in 36/40 (90%) of cases. In the remaining 4 
cases a third observer (MM) made the ultimate decision on OCT grading. 
2.2.8 MultiModalMapper Analysis 
A custom-made software tool (MultiModalMapper) was used for co-registration of microperimetry 
and SDOCT datasets (109). The microperimetry data consisted of 2 files that were imported into the 
software tool.  One file contains the actual perimetry data as well as mapping information for the 
second file, the fundus image. OCT data was exported as a binary volume file containing B-scans, 
confocal scanning laser ophthalmoscopy (cSLO) and B-scan segmentation data.  
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Microperimetry data and SDOCT data were aligned from corresponding landmarks set on both 
fundus images. Landmark selection was done manually using at least 3 landmarks.  The result of the 
co-registration process can be visualized immediately as overlay image to allow for adjustment by 
moving or adding additional landmarks. 
The transformed microperimetry data can then be visualised as an additional layer within the 3D 
view of the SDOCT.  Zoom and rotation of the 3D view as well as scrolling through B-scans and 
moving the SLO image and SDOCT scan together with the microperimetry layer are supported.  
The software also allows for the alignment of B-scans using retinal pigment epithelium segmentation 
data, which can be loaded from the volume file as well as extracted automatically using a Matlab 
(The MathWorks, Inc) script that processes the B-scans.  Segmentation borders can be altered 
manually in case of segmentation errors. 
 
2.2.9 Molecular analysis (undertaken by Dr Jill Cowing) 
Molecular analysis involved extraction of total genomic DNA from whole blood using the Gentra 
PureGene kit (Qiagen) following the standard protocol.  Coding exons and flanking exon-intron 
boundaries of CNGA3 and CNGB3 were PCR amplified using GoTaq Green Master Mix (Promega) and 
primer pairs. Bi-directional Sanger sequencing of each exon was carried out using the BigDye® 
Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) on an ABI 3730 DNA Analyzer.  Resulting 
sequences were analyzed for mutations by comparison with GenBank sequences using DNASTAR 
Lasergene SeqMan Pro. 
 
2.2.10 Statistical analysis 
Normality of data was assessed by evaluating the shape of histogram plots, with age, visual acuity, 
contrast sensitivity and reading acuity considered to be normally distributed.  Inter-eye correlations 
for all parameters were assessed using Pearson or Spearman correlation analysis where appropriate 
and significant correlations were found in all parameters.  The left eye was arbitrarily selected for 
further analysis (as no significant inter-eye difference was found between visual acuity, contrast 
sensitivity and reading acuity), and differences in parameters between OCT groups, fundus change 
category and genotype were assessed for using the one-way ANOVA or Kruskal-Wallis test where 
appropriate.  Differences in parameters between patients with or without foveal hypoplasia were 
assessed using either an independent samples T-test, or Mann-Whitney U test where appropriate. 
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3.1 RPE65 Trial 
3.1.1 Baseline characteristics 
12 subjects between ages of 6 and 23 were included in this study. Baseline visual acuity in the study 
eye ranged from 0.36 logMAR to 1.52 logMAR. Subjects 1 to 4 received the lower dose of vector, 
with subject 5 to 12 receiving the higher dose.  Follow-up length ranged from 8 months in two 
subjects, 12 months in two subjects, 24 months in four subjects, and 36 months in four subjects 
(Table 3). 
Subject Age RPE65 
Mutation 
Vector 
Dose 
Volume 
(ml) 
Foveal 
involvement 
Baseline Visual Acuity Follow-Up  
1 23 Y368H 
Y368H 
1x1011 0.9 Yes Study eye = 1.16 
Control eye = 0.88 
36 months 
2 17 IVS1+5g>a 
G40S 
1x1011 1 Yes Study eye = 1.52 
Control eye = 1.62 
36 months 
3 18 E6X 
D167Y 
1x1011 1 Yes Study eye = 0.76 
Control eye = 0.5 
36 months 
4 11 K298fs 
Y368H 
1x1011 1 Yes Study eye = 0.91 
Control eye = 0.75 
36 months 
5 23 Y368H 
Y368H 
1x1012 1 Yes Study eye = 0.36 
Control eye = 0.31 
24 months 
6 17 Y368H 
Y368H 
1x1012 1 Yes Study eye = 0.68 
Control eye = 0.53 
24 months 
7 10 IVS1+5g>a 
IVS12-2a>g 
1x1012 1 Yes Study eye = 0.44 
Control eye = 0.46 
24 months 
8 10 R91W 
R91W 
1x1012 1 Yes Study eye = 0.69 
Control eye = 0.64 
24 months 
9 6 IVS1+5g>a 
IVS1+5g>a 
1x1012 0.9 No Study eye = 0.82 
Control eye = 0.89 
12 months 
10 6 IVS1+5g>a 
Y368H 
1x1012 1 Yes Study eye = 0.8 
Control eye = 0.7 
12 months 
11 13 R124X 
F530fs 
1x1012 1 No Study eye = 0.63 
Control eye = 0.55 
8 months 
12 19 G40S 
G40S 
1x1012 1 Yes Study eye = 0.54 
Control eye = 0.6 
8 months 
Table 3 – Baseline characteristics, surgical details and follow-up time of subjects 
 
3.1.2 Surgical details 
All subjects underwent three port, pars-plana vitrectomy under general anaesthesia. Up to 1ml of 
rAAV vector was administered using a 41-gauge subretinal cannula (de Juan Synergistics) into the 
subretinal space.  Foveal involvement was achieved in 10 subjects, with a fluid-air exchange 
performed in 8 cases to manipulate the location of the induced retinal detachment to involve the 
fovea.  Approximately one third of the total retinal area was involved in all cases.  In 2 subjects (9 
and 11) foveal involvement did not occur despite fluid-air exchange. 
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3.1.3 Adverse events 
Two subjects (subjects 8 and 9) developed mild, asymptomatic episodes of inflammation, 
predominantly affecting the posterior segment.  In subject 8, mild vitritis, optic disc swelling with 
retinal vessel tortuosity and sheathing (Fig. 11a) was noted at the 6 week postoperative visit.  The 
subject was recommenced on a course of oral and topical steroid medication and the inflammation 
significantly improved over the next 2 weeks, and steroid medication was tapered and stopped over 
the next 2 months.  In subject 9, mild vitritis, optic disc swelling with retinal vessel tortuosity and 
sheathing (Fig. 11b) was noted at 3 weeks postoperatively.  The subject’s oral prednisolone dose was 
temporarily increased and the inflammation reduced over the next 3 weeks, with complete 
resolution at the 2 month visit.  Visual acuity was unaffected in both subjects, and no inflammation 
was noted in the control eyes.  
Subject 7 experienced mild anterior uveitis, 2 weeks after stopping the standard postoperative 
topical steroid course.  Topical steroids were recommenced and inflammation resolved with tapering 
of the steroid regime over the next 6 weeks.   
Subject 12 experienced mild distortion of vision in the study eye from 2 weeks postoperatively.  This 
symptom had improved but was still present at the most recent follow-up visit at 8 months. 
One subject experienced a rise in intraocular pressure to 34mmHg at 2 weeks postoperatively.  
Intraocular pressure soon returned to within normal limits following administration of topical ocular 
antihypertensive medication (G. Timolol 0.25% b.d.). 
Mild adverse effects attributed to oral steroid administration included transient glycosuria, lethargy, 
gastro-oesophageal reflux and facial acne exacerbation. 
 
Fig. 11a and 11b – Transient episodes of mild vitritis, optic disc swelling with retinal vessel 
tortuosity and sheathing observed in subjects 8 (Fig. 1a) and 9 (Fig. 1b).  Resolution of 
inflammation followed recommencement of oral steroid medication in both subjects and no 
inflammation was noted after the 4 month visit in subject 8, and inflammation had fully resolved 
by the 2 month visit in subject 9. 
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Fig. 11a        
 
Fig. 11b 
6 weeks 8 weeks
4 months 8 months
3 weeks 4 weeks
6 weeks 8 weeks
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3.1.4 Electrophysiological testing 
Baseline electrophysiology testing showed severe loss of generalised retinal function affecting rod 
and cone photoreceptors with severe macular involvement bilaterally, in all subjects. There was no 
significant change in electrophysiological testing in any of the subjects postoperatively. Multifocal 
ERGs showed severe widespread reduction pre and post-treatment. Pattern ERGs were undetectable 
pre and post-treatment in all subjects and the degree of subjects’ nystagmus was not an inhibiting 
factor in performing these tests.  
 
 
 
Fig. 12 – Standard ERG traces from subject 3. Top trace -preoperative study eye. Middle trace – 4 
months postoperative in study eye. Bottom trace – example of normal ERG. 
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3.1.5 Immunological Assays 
At various time points prior to and post-treatment, subjects’ serum was assessed for the presence of 
immune responses against the AAV2 capsid or the RPE65 transgene product.  
Table 4 shows the results of the neutralising antibody assay (NAb). Patient 7 was the only patient to 
show a persistent up-regulation of NAb after gene therapy. The increase in their NAb titre is 
concomitant with the removal of steroid therapy.  Patient 7’s NAb titre remained elevated for over 2 
years but is reducing with time. Patient 8 showed a slight increase in NAb titre at 4 months that has 
reduced to baseline levels.  Patient 9 showed a transient increase in NAb titre but this has greatly 
reduced with time after gene therapy.  Interestingly, even though patient 4 had quite a high NAb 
titre before gene therapy, this did not increase following administration of the gene therapy vector. 
No other patients showed any consistent increase in antibody titre for the duration of their follow 
up, indicating no up-regulation of humoral responses to AAV2 in these patients.  
Patient Base Day 1 Wk1 Wk2 Wk3 Wk4 Wk8 Mnth4 Mnth8 Yr 1 Yr2 Yr3 
1 4 3 4 4 4 6 5 6 … 4 12 16 
2 neat  neat neat neat neat 2 neat neat … 3 2 3 
3 Neat neat neat neat neat neat neat neat … neat neat 2 
4 512 512 1024 512 512 1024 1024 1024 … 512 256 200 
5 4 4 2 neat neat neat 1.5 neat 3 2 4 … 
6 2 neat 1.5 1.5 … neat neat neat neat neat 1.5 … 
7 2 1.5 2 neat 6 256 600 1024 1024 700 200 … 
8 1.5 neat 1.5 1.5 neat neat 4 16 3 6 3 … 
9 4 … 4 … … 256 200 32 … … … … 
10 1.5 neat neat neat neat 2 3 3 3 neat … … 
11 neat 1.5 1.5 1.5 2 neat neat neat 1.5 … … … 
12 neat neat 2 1.5 2 1.5 neat 3  … … … 
Table 4 - Circulating neutralising antibodies against AAV2.  Neutralising antibody titre: serum 
dilution that resulted in 50% inhibition of transduction of 293T cells by AAV2.GFP  
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Table 5 shows the results of the ELISA to detect circulating levels of IgA, IgG and IgM against RPE65. 
No patients showed any increase of greater than 1.5-fold compared to baseline in circulating IgA, IgG 
or IgM against the transgene product (RPE65) to date, except for patient 5, who had a transient 1.7-
fold titre increase at week 4, before dropping back to baseline levels, which could indicate a 
marginal humoral immune response against RPE65.  
Patient Day 1 Wk1 Wk2 Wk3 Wk4 Wk8 Mnth4 Mnth8 Yr 1 Yr2 Yr3 
1 116 95.7 70.3 71.6 97.1 83.7 101.1 … 134.5 92.6 160.0 
2 84 97.2 102.2 112.5 124.7 77.1 89.6 … 65.2 109.2 98.4 
3 99.3 82.8 90.3 81.5 81.5 100.2 94.5 … 130.6 122.8 130.7 
4 100.4 104.4 100 86.6 86.2 101.1 88.4 … 84.9 90.6 148.3 
5 111.9 107.7 135.5 129.1 169.1 102.2 93.6 98.4 96.5 99.6 … 
6 123.9 143 89.6 … 92.9 94.1 99.7 98.9 87.2 117 … 
7 91 105 96 90 103 83 86 127 100 96.3 … 
8 104.3 113.9 125.3 126.2 43.6 56.9 59.2 69.9 53.5 87.5 … 
9 … 67 … … 110.2 73 96 … … … … 
10 131.3 123 98.4 110.5 116.7 87.8 114 100 102.7 … … 
11 83.3 52.8 110.7 90.8 88.6 96.7 90.4 79.8 … … … 
12 91.8 94.7 93.3 101.9 96.6 94.5 96.8  … … … 
Table 5 - Serum ELISA to detect circulating levels of IgA, IgG and IgM against rRPE65. Relative 
antibody titre (%) compared to the baseline sample 
 
In table 6 the results of the ELISA to detect circulating levels of IgA, IgG and IgM against AAV2 are 
depicted. Patient 5 showed a transient increase of 2.34-2.03-fold in serum Ig against AAV2 in weeks 
3-8, which then resolved back to baseline levels.  Patient 7 showed an increase in circulating Ig 
against AAV2 between wk4-month 8 which is consistent with the increase in NAb titre against AAV2 
in this patient over the same time frame.  No other patients showed an increase of greater than 1.5 
fold within the first year after gene therapy.  Patient 1 and 7 had an increase of over 1.5 fold at year 
2, but this small spike in anti-AAV2 Ig is not consistent with a humoral response to a single 
administration of AAV2 vector and is more likely to result from re-exposure to wild type AAV2 within 
the environment.  
Patient Day 1 Wk1 Wk2 Wk3 Wk4 Wk8 Mnth4 Mnth8 Yr 1 Yr2 Yr3 
1 112.5 85.5 88.4 68.2 103 86.1 50.5 … 106.3 156.6 108.1 
2 74.0 85.0 110.0 99.3 86.2 85.7 89.6 … 70.3 94.4 74.4 
3 95.7 70.1 59.0 73.9 78.2 84.9 95.2 … 143.0 77.3 82.9 
4 82.7 90.1 93.0 65.8 70.5 64.8 88.7 … 79.6 185 130 
5 85.3 126.6 112.0 234.2 222.6 203.3 143.5 115.4 53.0 79.3 … 
6 100.4 96.4 112.2 … 117.5 110.0 123.4 122.5 125.8 139.7 … 
7 121.4 111.3 117.5 117.4 182.5 321.0 261.9 174.9 139.2 185.5 … 
8 87.2 106.9 98.6 101.8 123.9 106.1 100.5 91.4 72.9 95.4 … 
9 … 117.8 … … 99.9 107.9 116.0 … … … … 
10 109.6 105.6 91.6 94.0 95.6 75.1 95.2 116.1 97.3 … … 
11 95.7 71.4 107.6 106.5 101.7 102.2 98.7 90.0 … … … 
12 113.0 100.8 98.4 97.4 97.4 95.4 113.0  … … … 
Table 6 - Serum ELISA to detect circulating levels of IgA, IgG and IgM against AAV2. Relative 
antibody titre (%) compared to the baseline sample 
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Table 7 shows the result of an ELISpot assay to detect secretion by blood lymphocytes of the Th1 
cytokine IFN in response to co-culture with AAV2.  Patient 1 had a low positive response against 
AAV2 at baseline, but this positive response was not observed in any samples taken after gene 
therapy, indicating that administration of AAV2 to the eye did not further activate any AAV2-specific 
T-cells.  Four patients each showed a transient modest positive response at one time point only, 
which then resolved.  One of these was patient 7, who had a high concomitant increase in the NAb 
titre against AAV2 at the same time point (week 4). However, the T-cell response was not of the 
same magnitude, being much lower, was not sustained and had dropped back to negative levels by 
the week 8 time point, so is inconsistent with an effector T-cell response.  Patient 9 also had an 
increase in NAb titre at the same week 8 time point as the modest positive ELISpot result, although 
the NAb titre was already dropping from its peak at week 4.  The other two patients (patients 8 and 
10) with single positive ELISpot responses did not have any NAb response to AAV2 and there is no 
apparent reason for these very modest and transient increases in T-cell responses against AAV2. 
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Patient Test Base Day 
1 
Wk1 Wk2 Wk3 Wk4 Wk8 Mnth4 Mnth8 Yr 1 Yr2 Yr3 
1 Negative 7 14 14 8 19 13 109 89 … 74 3 305 
 Positive >300 >300 >300 >300 >300 >300 >300 >300 … 500 470 500 
 AAV 25 25 6 9 3 21 101 75 … 119 3 271 
2 Negative 3.5 0 2 4 1 4 8 1 … 20 20 3 
 Positive >300 374 >300 >300 412 >300 >300 >300 … 500 500 406 
 AAV 5.3 1 2 3 0 4 4 3 … 24 24 3 
3 Negative 11 13 5 6 6 7 48 89 … 14 11 20 
 Positive >300 >300 >300 >300 >300 >300 >300 >300 … 341 >500 >500 
 AAV 15 21 5 13 5 9 27 116 … 0 10 26 
4 Negative 143 155 6 6 7 4 41 7 … 6 3 26 
 Positive >300 >300 >300 >300 >300 >300 >300 696 … 147 364 615 
 AAV 155 118 5 4 4 7 39 11 … 9 1 7 
5 Negative 3 2 6 4 11 6 6 42 0 14 2 Pending 
 Positive 568 569 737 455 498 >500 528 500 508 575 744 Pending 
 AAV 1 4 8 4 9 10 7 21 2 6 3 Pending 
6 Negative 2 0 1 8 … 7 11 3 3 8 7 Pending 
 Positive 580 >500 >500 500 … 913 600 419 280 475 649 Pending 
 AAV 3 2 1 5 … 5 5 1 2 4 3 Pending 
7 Negative 10 3 39 6 11 34 4 13 33 17 6 Pending 
 Positive 451 388 501 444 500 500 567 327 409 425 359 Pending 
 AAV 12 5 40 8 14 70 8 13 46 12 8 Pending 
8 Negative 12 1 11 8 0 5 3 5 11 … 12 Pending 
 Positive 400 459 567 555 375 471 514 399 422 … 400 Pending 
 AAV 12 6 31 11 0 1 8 3 18 … 12 Pending 
9 Negative 66 … 8 … … 65 10 … … … Pending Pending 
 Positive 471 … 492 … … 576 632 … … … Pending Pending 
 AAV 56 … 9 … … 57 26 … … … Pending Pending 
10 Negative 16 9 3 3 5 11 7 8 9 1 Pending Pending 
 Positive 654 573 501 550 574 562 640 494 553 482 Pending Pending 
 AAV 30 9 3 4 5 25 9 5 7 1 Pending Pending 
11 Negative 6 1 6 5 3 5 5 13 40 Pending Pending Pending 
 Positive 447 461 573 464 498 410 514 613 480 Pending Pending Pending 
 AAV 13 1 5 6 6 2 4 17 21 Pending Pending Pending 
12 Negative 19 4 2 2 5 21 8 9  Pending Pending Pending 
 Positive 500 604 666 496 643 500 500 650  Pending Pending Pending 
 AAV 13 10 3 1 4 19 12 12  Pending Pending Pending 
Table 7 - ELISpot assay to detect secretion of the Th1 cytokine IFN in response to co-culture with 
AAV2.  Average spot counts from triplicate wells.  For positive controls, where spot counts were 
saturating, the ELISpot reader defined them as greater than 300 spots. A sample with at least twice 
as many spots in the AAV assay as in the negative control is considered to show a positive response. 
… = no sample was obtained. 
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3.1.6 Visual Acuity 
At 6 months following treatment, the visual acuity in 1 subject (subject 7) reduced (worsened) by 
more than 0.3 logMAR in their study eye, compared to baseline (Fig. 13a). No reduction in visual 
acuity of 0.3 logMAR or more was observed in the control eyes at 6 months.  Both the study and 
control eyes of subject 11 showed an improvement in acuity of 0.3 logMAR or more at 6 months.  In 
the study eye of 10 subjects with at least 12 months follow-up (subjects 1-10), the visual acuity 
reduced by 0.3 logMAR or more in 2 subjects (subjects 2 and 3) at their final visit (Fig. 13b).  No 
reduction in visual acuity of at least 0.3 logMAR was observed in the control eyes.  No subject with 
more than 12 months follow-up showed an improvement in visual acuity of more than 0.3 logMAR in 
either eye. 
 
Fig. 13a – Graph showing change in visual acuity from baseline at 6 months 
 
Fig. 13b – Graph showing change in visual acuity from baseline at final visit 
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3.1.7 Contrast sensitivity 
At 6 months following treatment, 2 subjects (subjects 7 and 12) had a reduction (worsening) in 
contrast sensitivity of at least 0.2 logCS in their study eye, and no control eye showed a reduction to 
this extent (Fig.14a).  Subjects 1, 8 and 9 showed an improvement of more than 0.2 logCS in their 
study eye, and subject 9 also had more than 0.2 logCS improvement in their control eye.  In the 
study eye of 10 subjects with at least 12 months follow-up, 3 subjects (subjects 3, 6 and 7) had a 
reduction in contrast sensitivity of at least 0.2 logCS at their final visit (Fig. 14b). No reduction of 
more than 0.2 logCS was observed in the control eye at similar time points.  Subjects 1 and 9 showed 
an improvement of more than 0.2 logCS in their study at final visit, and subject 9 also had a similar 
improvement in their control eye.  
 
Fig. 14a – Graph showing change in contrast sensitivity from baseline at 6 months
            
Fig. 14b – Graph showing change in contrast sensitivity from baseline at final visit 
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
1 2 3 4 5 6 7 8 9 10 11 12
C
h
an
ge
 in
 c
o
n
tr
as
t 
se
n
si
ti
vi
ty
 f
ro
m
 
b
as
e
lin
e
 a
t 
6
 m
o
n
th
s 
(l
o
gC
S)
Subject
Study eye
Control eye
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
1 2 3 4 5 6 7 8 9 10 11 12
C
h
an
ge
 in
 c
o
n
tr
as
t 
se
n
si
ti
vi
ty
 f
ro
m
 
b
as
e
lin
e
 a
t 
fi
n
al
 v
is
it
 (
lo
gC
S)
Subject
Study eye
Control eye
Improvement in 
contrast sensitivity 
Reduction in 
contrast sensitivity 
Improvement in 
contrast sensitivity 
Reduction in 
contrast sensitivity 
60 
 
3.1.8 Reading Acuity 
Reading acuity assessment was performed in 8 subject (4 younger subjects were unable to perform 
the reading test due to language difficulties), and a reduction (worsening) in reading acuity of at 
least 0.3 logMAR was observed in the study eye of 3 subjects (subjects 3, 7 and 12) at 6 months, and 
no control eye showed a reduction in reading acuity of at 0.3 logMAR or more (Fig. 15a).  In the 7 
subjects with at least 12 months follow-up of reading acuity assessment, reading acuity reduced by 
at least 0.3 logMAR in 3 subjects (subjects 1, 3 and 7) at their final visit (Fig. 15b).  No reduction in 
reading acuity of at least 0.3 logMAR was found in the control eye, and no eyes showed more than 
0.3 logMAR acuity of improvement.  
 
Fig. 15a – Graph showing change in reading acuity from baseline at 6 months 
 
Fig. 15b – Graph showing change in reading acuity from baseline at final visit 
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3.1.9 Dark-adapted Perimetry  
Figure 16 shows the results of the dark-adapted perimetry assessment. Six subjects (subject 3, 5, 6, 
8, 10 and 12) showed significant improvement in retinal sensitivity at various loci with dark-adapted 
perimetry testing using a blue light stimulus in their study eye.  Subject 3 displayed the greatest 
improvement with 54 locations (with mean sensitivity of 17dB- Fig. 17) showing significant 
improvement in retinal sensitivity at 4 months.  The level of peak improvement was not maintained, 
with retinal sensitivity declining by 12 months.  At 36 months, there were 5 remaining locations of 
improved sensitivity, which however maintained a high mean sensitivity of 21.2dB.  In addition, 
subject 3 displayed numerous loci of reduced retinal sensitivity in their control eye, with 19 and 13 
locations showing significant reduction in sensitivity at 24 and 36 months respectively, compared to 
a reduction at 8 locations at 24 months, and 4 locations at 36 months in their study eye (Fig. 18).  
Subject 6 showed progressive improvement to a peak of 46 locations (mean sensitivity 10dB) with 
significant sensitivity improvement at 12 months, with a decline in sensitivity to 21 locations (mean 
sensitivity 11.6dB) still displaying significantly improved sensitivity at 24 months.  Subject 5 had a 
peak of 26 locations (mean sensitivity 3.9dB) with significant improvement in sensitivity at 8 months, 
with 11 locations (mean sensitivity 7.5dB) still displaying significantly improved sensitivity at 24 
months.  Subject 8 had 2 time points of greatest improvement in sensitivity occurring at 6 and 12 
months.  The numbers of locations showing improvement in sensitivity at these time points were 17 
and 20 respectively.  In between these time points at 8 and 10 months, retinal sensitivity declined – 
possibly related to the episode of posterior segment inflammation with optic nerve involvement that 
this subject experienced.  Subject 10 showed a modest degree of improvement with a peak of 10 
locations (mean sensitivity 7.4dB) showing improved sensitivity at 8 months, with improvement 
declining to 5 locations (mean sensitivity 3.6dB) at 12 months.  Subject 12 showed an improvement 
at 3 locations (mean sensitivity 12.3dB) at 8 months.  In the control eye, two subjects (subjects 5 and 
6) showed significant improvement in retinal sensitivity at a maximum of 8 locations, occurring at 8 
months (mean sensitivity 2.8dB) in subject 5, and at 10 months (mean sensitivity 1.6dB) in subject 6 
(Fig. 19).   
In subject 3 the area of greatest sensitivity improvement occurred in the central 15 degrees, with 
extension towards 20 degrees inferiorly (Fig. 20).  In subject 5, the greatest improvement was seen 
within the central 10 degrees.  In subject 6, the area of greatest improvement occurred centrally and 
extended 15-20 degrees into the inferior hemifield.  In subject 8, the region of most significant 
improvement was in the superior-nasal field, with improvement also occurring in the periphery of 
the inferior-nasal field.  Similarly, subject 10 showed greatest improvement in the superior-nasal 
field.  Subject 12 showed improvement in the central 15 degrees. 
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Fig. 16 – Graph of number of dark adapted perimetry locations with significant improvement in 
retinal sensitivity in study eye 
 
 
 
 
Fig. 17 – Graph of mean sensitivity of locations showing significant improvement in sensitivity (dB)  
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Fig. 18 – Dark-adapted perimetry Progressor plots for subject 3.  Retinal sensitivity is represented 
by the lengths of the bars, with the long bars showing low sensitivity and the shorter bars showing 
improved sensitivity. Yellow indicates a decline in sensitivity that is not significant, red indicates a 
decline that is significant (p<0.05), and green indicates an improvement that is significant (<0.05).  
Several loci in the study eye continued to show significant improvement in sensitivity at 36 months 
follow-up, with high sensitivity (indicated by shorter green bars) maintained at central locations.  
There are many more loci in the control eye which show a significant reduction in sensitivity due to 
the natural progression of the disease from 12 to 36 months follow-up, compared to the study eye. 
Control eye Study eye
12 months
24 months
36 months
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Fig. 19 – Graph of number of dark adapted perimetry locations with significant change in retinal 
sensitivity in control eye 
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Fig. 20 – Plots of dark-adapted perimetry peak sensitivity improvement in subjects showing 
improvement 
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3.1.10 Microperimetry  
The results of the microperimetry assessment of retinal sensitivity are shown in figure 21 to 24. 
Improvement in retinal sensitivity with microperimetry testing occurred in six subjects (subjects 3, 5, 
6, 8, 10 and 12).  The largest improvement in sensitivity occurred in subject 6, who achieved a 6.4dB 
improvement in mean sensitivity from baseline, at 6 months (Fig. 21).  Peak sensitivity was not 
maintained with a decline in sensitivity to 2.09dB and 1.41dB at 12 and 24 months respectively (Fig. 
21 and 22).  Subject 5 achieved a peak improvement in mean sensitivity of 5.32dB at 8 months, and 
showed sustained improvement of over 5dB sensitivity at 24 months.  Subject 3 achieved a peak 
mean sensitivity of 4.47dB at 12 months, with sensitivity reducing to 0dB at 36 months.  As was 
observed with dark adapted perimetry testing, subject 8 had two peaks in retinal sensitivity, 
occurring at 2 months (2.31dB) and at 10 months (2.47dB), with retinal sensitivity declining to 
0.14dB at 6 months. A more modest improvement in mean sensitivity from 0.09dB at baseline to 
0.88dB at 6 months was seen in subject 10.  Subject 12 achieved a maximum mean retinal sensitivity 
of 2dB at 6 months.  Subject 7 had a reduction in mean sensitivity from 1.85 dB at baseline to 0.47dB 
at 6 months, with recovery to 1.08dB at 24 months.  No significant changes in mean retinal 
sensitivity occurred in the control eye of the six subjects who showed improvements in their study 
eye, or in the study or control eyes of the other subjects (Fig. 23). 
Plots of peak improvement in mean retinal sensitivity are depicted in Fig. 24. 
 
 
Fig. 21 – Graph of mean retinal sensitivity with microperimetry in subjects showing improvement 
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Fig. 22 – Plots of microperimetry retinal sensitivity in subject 6.  Blue circles indicate locations of 
improved sensitivity, and red circles indicate locations of declined sensitivity.  The size of the circles 
indicates retinal sensitivity on a scale of 0 to 14dB.  There is a progressive improvement in sensitivity 
in the study eye until 8 months, after which overall sensitivity declines, although focal locations of 
improved sensitivity remain. 
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Fig. 23 – Graph of mean retinal sensitivity with microperimetry in control eye of subjects showing 
improvement with study eye 
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Fig. 24 – Plots of maximum retinal sensitivity in six subjects showing improvement with 
microperimetry testing.   
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3.1.11 Visual Mobility Assessment 
Visual mobility is assessed in low light conditions by measuring the time taken by the subjects to 
navigate a simple maze and the number of navigation errors (loss of orientation or touching the 
barriers) made. Visual mobility improved in 5 subjects (subjects 3, 5, 6, 8 and 10) following 
treatment.  
In subject 3, the travel time reduced from 77 seconds at baseline to 14 seconds at 6 months for the 
study eye when performed at 4 Lux light level.  In addition, the number of mobility errors decreased 
from 8 to 0 during this period.  In the control eye, travel time reduced by a smaller amount from 36 
seconds at baseline to 12 seconds at 6 months, and mobility errors reduced from 1 to 0 at 4 Lux. 
Subject 5 was unable to perform mobility testing preoperatively at the 2 Lux and 4 Lux levels, due to 
insufficient ability to see the maze at these low light levels.  Postoperatively he was able to undergo 
assessment and made fewer errors in the study eye at both 2 Lux and 4 Lux compared to the control 
eye (Fig. 25a and b). 
Subject 6 was unable to perform assessment at 2 Lux preoperatively, but postoperatively he was 
able to undergo testing and made zero errors in the study eye, compared to 4 errors with the control 
eye.  At the 4 Lux level, there was a greater reduction in the errors made postoperatively in the 
study eye.  In addition, travel time was less using the study eye at these light levels (Fig. 25c and d). 
Subject 8 was unable to perform assessment at 2 Lux preoperatively, but postoperatively he was 
able to undergo testing and made zero errors in the study eye, compared to 8 errors with the control 
eye.  At the 4 Lux level, there was a reduction in mobility errors from 5 to 0 after treatment using the 
study eye, with no decrease in errors made using the control eye.  Travel times were also less when 
using the study eye at these light levels (Fig. 26a and b). 
Subject 10 could only perform assessment at the 4 Lux level postoperatively, and made zero mobility 
errors using the study eye, compared to 7 errors with the control eye.  In addition, the travel time 
was 10 seconds faster when using the study eye (Fig. 26c). 
Subject 12 had an increase in the travel time at the 4 Lux level from 67 seconds to 136 seconds in the 
study eye, and from 80 seconds to 105 seconds.  Mobility errors were similar at baseline and at 6 
months for both eyes (Fig. 26d).  
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Fig. 25 – Visual mobility plots for subjects 5 and 6 
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Fig. 26a-d - Visual mobility plots for subjects 8, 10 and 12 
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3.1.12 OCT Results 
Pre-operative and post-operative SDOCT imaging was performed in eight subjects. Examples of the 
images obtained are shown in figure 28 and 29.  Out of these eight subjects (subjects 5-12) five 
(subjects 5, 6, 7, 8 and 12) had a reduction in foveal thickness of over 15 µm (outside of test-retest 
variability) in their study eye at 6 months, with no control eye showing a similar reduction (Fig. 27a).  
In the six subjects (subjects 5-10) who underwent SDOCT and had at least 12 months follow-up, 
three subjects (subjects 5, 7, 8) had a reduction in foveal thickness of more than 15 µm (Fig. 27b) at 
final visit.  At 24 months, the degree of retinal thinning in subject 6 had lessened to 14 µm, 
compared to 30 µm at their 6 month visit.  The control eye of subject 5 also had a reduction in foveal 
thickness of more than 15 µm at 24 months.  In all five subjects who showed a significant reduction 
in foveal thickness, thinning of the outer nuclear and photoreceptor layers were a common finding,  
with subjects 5, 6, 7 and 12 also showing disruption or disappearance of the IS/OS line.  Subject 7 
also had disruption of the ELM (Fig. 28a and 28b).  No retinal thinning occurred in subject 10 (aged 6 
years) who also underwent foveal injection (Fig. 29a and 29b). 
In the four subjects (subjects 1-4) who only underwent time-domain OCT, retinal thinning outside of 
test-retest variability occurred in both the study and control eyes of subjects 1 and 3 at 6 months.  At 
final follow-up visit of 36 months, significant retinal thinning had occurred in the study eye of 
subjects 3 and 4, and in the control eye of subjects 1 and 3. 
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Fig. 27a – Graph showing change in foveal thickness from baseline at 6 months in subjects who 
underwent SDOCT imaging 
 
Fig.27b – Graph showing change in foveal thickness from baseline at final visit in subjects who 
underwent SDOCT imaging 
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Fig. 28a – OCT at baseline of study eye in subject 7, showing intact IS/OS line and ELM.  At 6 
months (Fig. 228b), retinal thinning and disruption of the IS/OS line and ELM have occurred. 
 
                
  
 
Fig. 29a – OCT at baseline of subject 10 (aged 6) study eye showing intact IS/OS line and ELM, with 
no retinal thinning or disruption to these layers occurring at 6 months (Fig. 29b). 
Correlation of OCT changes with visual acuity 
In the 5 subjects with evidence of retinal thinning and disruption on SDOCT imaging, 2 subjects 
(subjects 7 and 12) also experienced considerable reductions in visual acuity, contrast sensitivity and 
reading acuity.  Both of these subjects showed disruption of the IS/OS junction, with involvement of 
the ELM in subject 7.  Subject 6 showed disruption of the IS/OS junction and had a reduction in 
contrast sensitivity (of more than 0.2 logCS) but not in visual or reading acuity.  Subjects 5 and 8 did 
not have any significant reduction in vision, nor show disruption in the IS/OS junction or ELM. 
In the 5 subjects who showed foveal thinning of more than 20 microns at 6 months in their study 
eye, the greatest reduction in thickness occurred by 5 days after treatment in 4 out of the 5 subjects, 
and by 2 weeks in the remaining subject (Fig. 30a).  No significant thinning occurred in the control 
eyes of these subjects at these time points (Fig. 30b). 
ELM IS/OS line 
29a 29b 
28a 28b 
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Fig. 30a – Graph showing foveal thickness in the early postoperative period in the study eye 
 
Fig. 30b – Graph showing foveal thickness in the early postoperative period in the control eye 
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3.2 Retinal structure and function in Achromatopsia: implications for gene 
therapy  
3.2.1 Clinical examination 
Twenty male and 20 female subjects with a mean age of 24.9 years (range 6 to 52) were included in 
this study (Table 8). Mean visual acuity was 0.92 logMAR (range 0.72 to 1.32), mean contrast 
sensitivity was 1.16 logCS (range 0.50 to 1.55), and mean reading acuity was 0.76 logMAR (range 0.5 
to 1.32). There was no significant correlation between age and visual acuity (r=0.18, p=0.27, Fig. 31), 
contrast sensitivity (r= -0.27, p=0.09) or reading acuity (r=0.29, p=0.07). 
All patients were able to read the Ishihara test plate, but were unable to read any subsequent plates, 
or correctly identify any of the HRR test plates.  
Fundus examination revealed no evidence of macular retinal pigment epithelial (RPE) disturbance in 
11 patients (mean age 19.5 years; range 6-33), RPE disturbance in 20 patients (mean age 27.5 years; 
range 12-52), and well-circumscribed macular atrophy in 9 patients (mean age 25.9 years; range 11 
to 43) with no significant difference in mean age, visual acuity, contrast sensitivity or reading acuity 
between these three groups (Table 9). 
 
Fig. 31 – Graph showing no significant correlation between age and visual acuity (r=0.18, p=0.27) 
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Variable Mean (SD) Range Median 
Age (years) 24.9 (12.3) 6-52 23.5 
Visual acuity (logMAR) 0.92 (0.13) 0.72-1.32 0.9 
Contrast sensitivity (logCS) 1.16 (0.23) 0.50-1.55 1.2 
Reading acuity (logMAR) 0.76 (0.19) 0.50-1.32 0.73 
Retinal sensitivity (dB) 16.6 (3.4) 3.1-19.9 17.6 
BCEA (degrees) 13.5 (13.5) 1.7-65 7.7 
    
Genotype 
CNGA3 
CNGB3 
GNAT2 
PDE6C 
Unknown 
n (%) 
17 (42.5) 
15 (37.5) 
4 (10) 
1 (2.5) 
3 (7.5) 
  
OCT category 
1 
2 
3 
4 
5 
Foveal hypoplasia 
No 
Yes 
Unrecordable 
n (%) 
9 (22.5) 
13 (32.5) 
6 (15) 
9 (22.5) 
3 (7.5 
N (%) 
16 (40%) 
21 (52.5) 
3 (7.5) 
  
Fundus appearance category 
1 
2 
3 
n (%) 
11 (28) 
20 (50) 
9 (22) 
  
Table 8 – Clinical characteristics of patients. OCT category: 1=continuous ISe; 2=ISe disruption; 
3=ISe absence; 4=Hyporeflective zone present; 5=Atrophic outer retina. Fundus appearance 
category: 1=no RPE disturbance; 2=RPE disturbance; 3=atrophy present 
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Fundus appearance 
category 
1 2 3  
    p value 
Age (years) 
Mean (SD) 
Range 
Median 
 
19.5 (10.6) 
6-33 
22 
 
27.5 (13.7) 
12-52 
23.5 
 
25.9 (9.9) 
11-43 
25 
 
 
 
0.22 
Visual acuity 
(logMAR) 
Mean (SD) 
Range 
Median 
 
 
0.92 (0.13) 
0.72-1.16 
0.9 
 
 
0.90 (0.09) 
0.74-1.1 
0.9 
 
 
0.94 (0.2) 
0.8-1.32 
0.84 
 
 
 
 
0.68 
Contrast sensitivity 
(logCS)  
Mean (SD) 
Range 
Median 
 
 
1.22 (0.19) 
0.90-1.45 
1.25 
 
 
1.18 (0.24) 
0.70-1.55 
1.2 
 
 
1.06 (0.21) 
0.50-0.9 
0.7 
 
 
 
 
0.25 
Reading acuity 
(logMAR) 
Mean (SD) 
Range 
Median 
 
 
0.77 (0.15) 
0.58-1.00 
0.8 
 
 
0.77 (0.23) 
0.54 -1.05 
0.7 
 
 
0.72 (0.14) 
0.5-0.9 
0.7 
 
 
 
 
0.8 
Retinal sensitivity 
(dB) 
Mean (SD) 
Range 
Median 
 
 
16.9 (1.9) 
14.9-19.8 
17.6 
 
 
17.3 (2.6) 
12.8-19.9 
18.4 
 
 
14.5 (5.5) 
3.1-19.7 
16.7 
 
 
 
 
0.38 
BCEA (degrees) 
Mean (SD) 
Range 
Median 
 
19.5 (20.9) 
3.9-65 
13.7 
 
10.3 (8.6) 
2.3-38.5 
7.4 
 
13.2 (9.7) 
2.5-32.9 
15.1 
 
 
 
0.69 
Table 9 - Mean, standard deviation, range and median values of testing parameters in different 
fundus appearance categories. 1=no RPE disturbance; 2=RPE disturbance; 3=atrophy present 
 
 
 
 
 
 
80 
 
3.2.2 Retinal morphology 
On the basis of SDOCT imaging, subjects were placed into one of 5 OCT groups: (i) 9 patients (22.5%) 
had a continuous inner segment ellipsoid (ISe) layer at the fovea (mean age 26.8 years; range 6 to 52); 
(ii) 13 (32.5%) had ISe disruption (mean age 24.4 years; range 11 to 34); (iii) 6 (15%) had an absent ISe 
layer at the fovea (mean age 22.7 years; range 7 to 43); (iv) 9 (22.5%) had a hyporeflective zone (HRZ) 
(mean age 28.2; range 11 to 49); and (v) the remaining 3 subjects (7.5%) had evidence of outer retinal 
atrophy, including RPE loss (mean age 25 years; range 23 to 27) (Table 10).  
There were no significant differences in the age (p=0.54), visual acuity (p=0.14) or contrast sensitivity 
(p=0.42) between patients in the five OCT categories; however intriguingly reading acuity was 
significantly lower (p=0.09) in patients with no ISe disruption compared to patients with a HRZ (Table 
10).  Figure 32 shows representative SDOCT images of patients of different ages.   
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Fig. 32 – SDOCT appearance in patients of various ages.  No IS/OS disruption is present in (a) or in 
(b), who is aged 52.  IS/OS disruption is present in an 11 year old (c) and in (d).  HRZ presence is 
shown in (e) and (f), with complete cone loss occurring in (g) and (h). 
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OCT Group 1 (n=9) 2 (n=13) 3 (n=6) 4 (n=9) 5 (n=3)  
      p value 
Age (yrs) 
Mean (SD) 
Range 
Median 
 
26.8 (18.0) 
6-52 
24 
 
22.4 (9.4) 
11-34 
22 
 
22.7 (12.0) 
7-43 
21 
 
28.2 (12.8) 
11-49 
28 
 
25 (2) 
23-27 
25 
 
 
 
0.83 
Visual acuity 
(logMAR) 
Mean (SD) 
Range 
Median 
 
 
0.95 (0.13) 
0.72-1.1 
0.94 
 
 
0.92 (0.10) 
0.76-1.16 
0.9 
 
 
0.95 (0.19) 
0.8-1.32 
0.9 
 
 
0.85 (0.08) 
0.74-0.96 
0.86 
 
 
0.93 (0.23) 
0.76-1.2 
0.84 
 
 
 
 
0.48 
Contrast 
sensitivity 
(logCS) 
Mean (SD) 
Range 
Median 
 
 
 
1.09 (0.33) 
0.5-1.45 
1.2 
 
 
 
1.11 (0.23) 
0.65-1.35 
1.05 
 
 
 
1.21 (0.15) 
1.05-1.45 
1.2 
 
 
 
1.25 (0.13) 
1.05-1.45 
1.25 
 
 
 
1.25 (0.1) 
1.15-1.35 
1.25 
 
 
 
 
 
0.47 
Reading acuity 
(logMAR) 
Mean (SD) 
Range 
Median 
 
 
0.92 (0.25) 
0.6-1.32 
0.99 
 
 
0.76 (0.13) 
0.54-0.9 
0.8 
 
 
0.70 (0.16) 
0.5-0.9 
0.65 
 
 
0.66 (0.13) 
0.5-0.92 
0.68 
 
 
0.68 (0.11) 
0.56-0.77 
0.7 
 
 
 
 
0.02 
Retinal 
sensitivity (dB) 
Mean (SD) 
Range 
Median 
 
 
16.1 (2.8) 
12.8-19.8 
14.9 
 
 
17.4 (2.1) 
13.6-19.8 
17.6 
 
 
16.3 (4.5) 
7.8-19.9 
18 
 
 
17.4 (2.1) 
14.3-19.7 
17.8 
 
 
12.3 (8.1) 
3.1-18.4 
15.4 
 
 
 
 
0.70 
BCEA (degrees) 
Mean (SD) 
Range 
Median 
 
21.3 (19.7) 
3.8-40.8 
14.4 
 
9.9 (4.9) 
2.5-16.8 
9.4 
 
15.7 (14.8) 
4.7-44 
11.3 
 
9.2 (11.9) 
1.7-37.5 
3.75 
 
14.3 (11.6) 
3.6-32.9 
6.4 
 
 
 
0.18 
Table 10 – Mean, standard deviation, range and median values of testing parameters in different 
OCT categories. OCT category 1=continuous ISe; 2=ISe disruption; 3=ISe absence; 4=Hyporeflective 
zone present; 5=Atrophic outer retina. Bonferroni post-hoc analysis shows a significant difference 
in reading acuity between OCT category 1 and 4 
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Foveal hypoplasia, defined as the persistence of one or more inner retinal layers (outer plexiform 
layer, inner nuclear layer, inner plexiform layer or ganglion cell layer) through the foveal centre, was 
found in 21 (52.5%) patients; with it not being possible to assess hypoplasia in 3 patients due to severe 
foveal atrophy.  There was no significant difference in age, visual acuity, reading acuity or fixation 
stability between patients with or without foveal hypoplasia.  Contrast sensitivity (p=0.02) and retinal 
sensitivity (p=0.03) were higher in patients with evidence of foveal hypoplasia compared to those 
without (Table 11). 
Hypoplasia  No (n=16) Yes (n=21)  
   p value 
Age (yrs) 
Mean (SD) 
Range 
Median 
 
27.5 (14.6) 
6-52 
26.5 
 
22 (10.3) 
7-49 
22 
 
 
 
0.08 
Visual acuity (logMAR) 
Mean (SD) 
Range 
Median 
 
0.96 (0.11) 
0.72-1.16 
0.95 
 
0.85 (0.07) 
0.74-0.96 
0.86 
 
 
 
0.14 
Contrast sensitivity 
(logCS) 
Mean (SD) 
Range 
Median 
 
 
1.07 (0.29) 
0.5-1.55 
1.05 
 
 
1.23 (0.14) 
0.9-1.45 
1.25 
 
 
 
 
0.02 
Reading acuity 
(logMAR) 
Mean (SD) 
Range 
Median 
 
0.90 (0.18) 
0.6-1.32 
0.86 
 
0.65 (0.12) 
0.5-0.9 
0.62 
 
 
 
0.19 
Retinal sensitivity (dB) 
Mean (SD) 
Range 
Median 
 
16.2 (2.4) 
12.8-19.8 
15.6 
 
17.9 (1.86) 
13.8-19.8 
18.4 
 
 
 
0.03 
BCEA (degrees) 
Mean (SD) 
Range 
Median 
 
15.0 (16.6) 
1.7-40.7 
8.6 
 
11.7 (10.9) 
3.7-37.4 
7.3 
 
 
 
0.56 
Mutation 
CNGA3 
CNGB3 
GNAT2 
PDE6C 
Unknown 
% 
31 
38 
25 
U 
6 
% 
52 
38 
0 
U 
10 
 
Table 11 - Mean, standard deviation, range and median values of testing parameters in patients 
with and without foveal hypoplasia.  The percentage of patients within genotypes is also shown. 
U=unclassifiable. 
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3.2.3 Microperimetry 
All 40 patients underwent microperimetry testing on two occasions.  There were significant 
correlations in mean retinal sensitivity and fixation stability between both eyes, and further analysis 
was performed using the left eye. No significant difference in mean retinal sensitivity or fixation 
stability was found between patients’ first and second test, and the mean of these two tests was 
used for subsequent analysis. The mean retinal sensitivity of the group was 16.6 dB (range 3.1 to 
19.9 dB) and significant negative correlations were found between retinal sensitivity and age (rho= -
0.39, p=0.01, Fig. 33), visual acuity (rho= -0.44, p<0.01, Fig. 34) and reading acuity (rho= -0.55, 
p=<0.01). Surprisingly, a significant correlation was found between lower contrast sensitivity and a 
higher microperimetry score (rho=0.35, p=0.03).  There was no significant difference in the retinal 
sensitivity or fixation stability (p=0.30) between OCT groups (p=0.24, Table 10).  There was a 
significant correlation between fixation stability and visual acuity (rho=0.43, p<0.01), and 
unexpectedly, lower contrast sensitivity was significantly associated with a higher fixation stability 
(rho= -0.43, p<0.01).   
Six patients had a scotoma (defined as 0 dB retinal sensitivity in at least any 1 location) with a mean 
retinal sensitivity in this group of 11.0 db (range 3.1 to 14.8 dB), and mean fixation stability of 12.8 
(range 1.7 to 24).  The mean age of these patients was 40.2 years (range 25 to 52 years), and mean 
visual acuity was 1.01 logMAR (range 0.8 to 1.32).  Four of these 6 patients had RPE disturbance on 
fundus examination, with the remaining 2 patients having macular atrophy.  Variable macular 
structure was seen on SDOCT, with 3 of the 6 subjects having a normal ISe layer, and 1 patient 
having either an absent foveal ISe layer, or HRZ, or outer retinal atrophy respectively.   
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Fig. 33 – Graph showing a significant negative correlation between age and retinal sensitivity             
(rho= -0.39, p=0.01) 
 
Fig. 34 – Graph showing a significant negative correlation between visual acuity and retinal 
sensitivity (rho= -0.44, p<0.01) 
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3.2.4 Molecular Genetics 
Seventeen patients (42.5%) had CNGA3 mutations (mean age 24.8 years; range 7-49), 15 (37.5%) had 
CNGB3 mutations (mean age 20.4 years; range 6-47), 4 (10%) had GNAT2 mutations (mean age 43.3 
years; range 29-52), and 1 subject had a PDE6C mutation.  No sequence variants were found in 3 
individuals. 
3.2.5 Genotype-phenotype correlation 
The majority (80%) of patients in our study had either CNGA3 or CNGB3 mutations.  Statistical 
analysis between the patients with these two genotypes showed no significant difference in terms of 
age, visual acuity, contrast sensitivity, reading acuity, or fixation stability (Table 12).  However, 
retinal sensitivity was greater in the CNGB3 group compared to the CNGA3 group (18.1dB versus 
16.1dB, p=0.04).   
A comparison of the SDOCT images in the two genotype groups showed that 26.7% (n=4) of patients 
with CNGB3 mutations had no ISe disruption, compared to 5.9% (n=1) with CNGA3 sequence 
variants; and fewer (33.3%, n=5) patients harbouring CNGB3 variants had ISe disruption compared to 
47% (n=8) in the CNGA3 group.  The percentage of patients with a HRZ was similar in both groups - 
23.5% (n=4; CNGA3) and 26.7% (n=4; CNGB3). An atrophic outer retina was observed in 13.3 % (n=2) 
of CNGB3 patients compared to 5.9% (n=1) of CNGA3 patients. In the CNGA3 group, 69% (n=11) of 
patients had foveal hypoplasia, compared to 57% (n=8) of CNGB3 patients.  Foveal hyperplasia was 
not present in any patient with a GNAT2 mutation (n=4), and the single PDE6C patient had severe 
foveal atrophy.  On clinical examination, 41% (n=7) of CNGA3 patients had a normal fundus 
appearance, compared to 20% (n=3) of patients in the CNGB3 group, and also fewer (35%; n=6) 
CNGA3 patients had RPE disturbance compared to subjects with CNGB3 variants (53%; n=8).  The 
percentage of patients with macular atrophy was similar in both groups (CNGA3 - 24%,n=4 and 
CNGB3 - 27%, n=4). Only one (CNGA3 subject) of the six patients with a scotoma on microperimetry 
harboured variants in either of these two genes. The remaining 5 individuals had GNAT2 mutations 
(n=4) and PDE6C variants (n=1). In addition, visual acuity, contrast sensitivity, reading acuity and 
mean retinal sensitivity were lower in these genotypes, compared to the CNGA3 or CNGB3 groups; 
however the mean age of patients with either GNAT2 or PDE6C mutations was considerably higher 
than the CNGA3/CNGB3 group and moreover reliable comparisons are limited by the relatively small 
number of patients harbouring these rarer genotypes (Table 12).  Interestingly, 3 out of the 4 
patients with GNAT2 mutations had an intact ISe layer, despite a relatively low mean retinal 
sensitivity of 13.6dB and all of these patients having a central scotoma on microperimetry.   
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Genotype CNGA3 (n=17) CNGB3 (n=15) GNAT2 (n=4) PDE6C (n=1)  
     p value  
Age (yrs) 
Mean (SD) 
Range 
Median 
 
24.8 (10.4) 
7-49 
25 
 
20.4 (11.0) 
6-47 
18 
 
43.3 (10.2) 
29-52 
46 
 
43 
 
 
 
0.21 
Visual acuity 
(logMAR) 
Mean (SD) 
Range 
Median 
 
 
0.88 (0.1) 
0.74-1.16 
0.9 
 
 
0.90 (0.13) 
0.72-1.2 
0.9 
 
 
0.98 (0.09) 
0.88-1.1 
0.97 
 
 
1.32 
 
 
 
 
0.76 
Contrast 
sensitivity 
(logCS) 
Mean (SD) 
Range 
Median 
 
 
 
1.19 (0.21) 
0.65-1.55 
1.2 
 
 
 
1.21 (0.16) 
0.9-1.45 
1.25 
 
 
 
0.86 (0.32) 
0.5-1.2 
0.88 
 
 
 
1.05 
 
 
 
 
 
0.91 
Reading 
acuity 
(logMAR) 
Mean (SD) 
Range 
Median 
 
 
 
0.72 (0.13) 
0.5-0.9 
0.7 
 
 
 
0.73 (0.16) 
0.54-1.00 
0.7 
 
 
 
1.12 (0.17) 
0.92-1.32 
1.13 
 
 
 
0.9 
 
 
 
 
 
0.96 
Retinal 
sensitivity 
(dB) 
Mean (SD) 
Range 
Median 
 
 
 
16.1 (3.9) 
3.1-19.6 
17.6 
 
 
 
18.1 (1.76) 
15.4-19.8 
18.4 
 
 
 
13.8 (0.96) 
12.8-14.8 
13.7 
 
 
 
7.8 
 
 
 
 
 
 
 
0.04 
BCEA 
(degrees) 
Mean (SD) 
Range 
Median 
 
 
12.1 (11.9) 
2-44 
7.7 
 
 
13.2 (16.3) 
3.7-65 
7.3 
 
 
14.0 (9.8) 
1.7-24 
15.1 
 
 
17.1 
 
 
 
 
0.82 
OCT group  
1 
2 
3 
4 
5 
% 
5.9 
47 
17.6 
23.5 
5.9 
% 
26.7 
33.3 
0 
26.7 
13.3 
% 
75 
0 
0 
25 
0 
 
 
 
100 
 
Fundus 
appearance 
1 
2 
3 
 
% 
41 
35 
24 
 
% 
20 
53 
27 
 
% 
0 
100 
0 
  
Table 12 - Mean, standard deviation, range and median values of testing parameters in different 
genotype categories.  Statistical comparisons are between CNGA3 and CNGB3 groups only. The 
percentage of patients within genotypes with the various OCT and fundus changes is also shown. 
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3.2.6 Structure-Function Correlation using MMM 
Five patients from each of the CNGA3 and CNGB3 groups, and 3 patients with GNAT2 mutations, 
underwent MMM analysis, which allows co-registration of microperimetry with SDOCT imaging.  A 
consistent correlation between retinal structure and function was not found, with 4 out of 5 CNGB3 
patients having either ISe absence or HRZ presence, still displaying at least 16dB retinal sensitivity in 
these areas of outer retinal change.  In the 3 CNGA3 patients with either ISe absence or HRZ 
presence, 2 patients had a reduction in retinal sensitivity to at least 10dB. All three of the GNAT2 
patients had locations with 0dB sensitivity, with 2 of these patients having normal outer retinal 
structure. Fig. 35 shows MMM examples of inconsistent structure-function correlation. 
 
Fig. 35 – Overlay of SDOCT and Microperimetry, illustrating an inconsistent structure-function 
relationship. Retinal sensitivity derived from microperimetry is presented according to the scale 
panel in 2dB steps. Normal sensitivity is indicated by green colour and reduce sensitivity is indicated 
by red. Open red squares represent absolute defects. 
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 In (a) Retinal sensitivity is reduced (red square) in a region corresponding with HRZ presence.  In (b), 
reduced retinal sensitivity occurs in an area of complete cone loss with RPE involvement in a subject 
with a CNGA3 mutation. The extent of foveal atrophy and photoreceptor loss in this patient was not 
typical of other CNGA3 patients who had generally lesser degrees of retinal atrophy.  However, in 
(c), retinal sensitivity is reduced despite there being no IS/OS disruption, and in (d), retinal sensitivity 
is high (green squares) in a region of HRZ presence in a CNGB3 patient. 
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Discussion 
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4.1 RPE65 Trials 
The commencement of 3 clinical gene therapy trials for RPE65 deficiency within a similar time period 
has given an opportunity to evaluate the results from a relatively large number of subjects, and to 
assess whether differences in treatment strategies have an impact on safety and efficacy.  The 
results from each trial are individually discussed, followed by a collective summary of the pertinent 
results.  
4.1.3 Bainbridge/Ali group 
In this study, 12 subjects aged from 6 to 23 years underwent vitrectomy and subretinal 
rAAV2/2.hRPE65p.hRPE65 injection.  A human RPE65 promoter was used in this trial with the aim of 
limiting gene expression to RPE cells, instead of the more ubiquitous expression that occurs with the 
chicken β-actin promoter used in the two US trials (110, 111).  Two different dose levels were used 
with the first 4 subjects receiving the lower dose of 1x1011 vector genomes, and the remaining 8 
subjects receiving the higher dose of 1x1012 vector genomes.  Foveal detachment was induced in 10 
of the 12 eyes and follow-up ranged from 8 months to 3 years post treatment. 
No significant adverse immune events occurred in this study.  Subject 7 had a rise in neutralising 
antibodies and circulating antibodies to AAV2 between week 4 and month 8.  This subject 
experienced mild anterior uveitis at week 6, and this responded to a further short period of topical 
steroid therapy.  Tear samples were transiently positive at low levels for vector DNA sequences in 1 
low dose subject and 2 high dose subjects (subjects 7 and 10) at 1 day after surgery only.  No 
detection of vector DNA was found in peripheral blood or saliva in any subject. 
Subjects 8 and 9 experienced mild and transient intraocular inflammatory episodes, which in both 
cases were asymptomatic, had no evidence of an adverse effect on visual function and resolved 
following a further course of oral corticosteroids.  Both of these subjects had mild rises in 
neutralising antibodies to AAV2 which occurred at similar times to their periods of intraocular 
inflammation, suggesting that the inflammation may have arisen from an immune response to 
residual vector capsid.   
One of these subjects showed improvement in both microperimetry and dark adapted perimetry, 
but their improvement was uniquely fluctuating with a temporary decline in retinal sensitivity with 
microperimetry between months 4 and 6, and occurring between months 8 and 10 with dark 
adapted perimetry testing.  This patient had a mild degree of optic nerve head swelling 6 weeks 
following surgery, with the intraocular inflammation settling between months 2 and 3.  The timing of 
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inflammation preceded the temporary reduction in retinal sensitivity improvement, and although 
the optic nerve inflammation was not associated with an adverse effect on visual acuity, it may have 
limited the improvement evident on perimetric testing.  It is unclear why the decline in sensitivity 
occurred earlier with microperimetry, but may be due to the greater degree of cone involvement 
with this test and cone responses possibly being more susceptible than rod responses to optic nerve 
inflammation. 
Reductions in reading acuity greater than 0.3 logMAR occurred in the study eye of 3 out of 8 subjects 
tested at 6 months.  1 further subject had a significant reduction in reading acuity at their final 
follow-up visit at 36 months, and no significant reductions occurred in the control eyes.  Subject 7 
was the only subject with significant reductions in both visual and reading acuity.   2 subjects had no 
significant reduction in visual acuity at 6 months (0.06 logMAR reduction in subject 2 and no change 
in subject 3), but both had a 0.32 logMAR visual acuity reduction at 36 months, possibly suggesting 
that continued disease progression may have accounted for this – although similar reductions in 
acuity were not observed in the control eyes.  Subject 12 had a visual acuity reduction of 0.26 
logMAR  associated with a subjective deterioration in visual acuity .  Subject 11 had more than a 0.3 
logMAR improvement in acuity in both eyes at 6 months, but not at their last follow-up visit, 
suggesting that a learning effect may account for these changes.  
 A significant reduction in foveal thickness occurred in 5 out of the 8 subjects who underwent 
SDOCT, with a mean decrease of 51 microns in their study eye, compared to a mean decrease of 1 
micron in the their control eye.  All these subjects had subretinal injections involving the fovea.  In 
the 4 subjects with at least 24 months of follow-up, foveal thickness remained significantly reduced 
compared to baseline in 3 subjects. The extent of foveal thinning recovered in subject 6, from 30 
microns at 6 months to 14 microns at 24 months.  Subject 10 (aged 6 years), who also underwent 
foveal detachment, did not develop foveal thinning.  No foveal thinning was evident in the 2 subjects 
whose treatment area did not involve the fovea.   
The reduction in foveal thickness seen in the 5 subjects was primarily attributable to changes in 
outer retinal structures.  Thinning of the outer nuclear and photoreceptor layers were consistent 
findings.  The IS/OS junction and the ELM structures were most well defined preoperatively in 
subject 7, and postoperatively there was significant disruption to both of these layers, with this 
subject also experiencing the largest reductions in visual acuity. 
Structural changes reported to occur following rhegmatogenous retinal detachment include 
disruption of the inner segment/outer segment junction and the external limiting membrane (112, 
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113).  Postoperative visual acuity has been correlated with the integrity of these layers following 
detachment repair and also, inner segment/outer segment disruption has only been reported to 
occur in macula-off detachments (112).  The predictable adverse impact of retinal detachment on 
retinal structure and function may be dependent on the duration and height of the detachment.  A 
shallower preoperative height of macula-off detachments has been shown to correlate with a better 
postoperative visual acuity (114, 115), in animal models of retinal detachment providing evidence 
that PR degeneration increases with the distance between the RPE and PR layers in experimental 
detachments.  PR degeneration has been shown to be reduced by maintaining hyperoxic conditions 
during the period of detachment in a feline model of retinal detachment (116).  This suggests that 
the loss of oxygen supply to the retina from the choriocapillaris is an important factor in the outer 
retinal disruption that can occur after detachment.  In higher macula-off detachments, the greater 
amount of subretinal fluid present may make the diffusion of oxygen and other nutrients more 
difficult to the outer retina, therefore possibly contributing to the greater amount of PR 
degeneration and worse visual outcomes.   
However, a significant degree of retinal thinning was observed in the treated eye of a number of 
subjects with fovea involving injections in both this study and that described by the Jacobson group, 
despite considerably less volume of fluid injected in the Jacobson study. These findings underline the 
importance of carefully weighing the balance of risk and when considering subfoveal vector injection 
for gene therapy. Eyes with good visual acuity at the time of intervention are more likely to sustain 
detachment-mediated deterioration in acuity than those with poor acuity at baseline 
In 4 out of the 5 subjects with significant foveal thinning with SDOCT, the greatest reduction in 
thickness occurred within 1 week following surgery, and by 2 weeks in the remaining subject.  
Various animal models have shown that retinal detachment induces PR cell apoptosis which follows 
a consistent timeline of apoptotic PR cells seen within a few hours, peaks at 2 to 3 days and then 
reduces to a  low level after day 7 following retinal detachment (117, 118).  A similar pattern of PR 
apoptosis has also been found following retinal detachment in humans, with apoptosis occurring 
within 24 hours, peaking at day 2 and dropping to a low level after day 7 (119).  The timing of the 
largest reductions in retinal thickness seen in our subjects is in keeping with the experimental 
evidence of PR death occurring relatively early following retinal detachment. 
Significant improvements in retinal sensitivity with dark adapted perimetry using a blue light 
stimulus occurred in the study eye of 6 subjects.  Subjects 3, 5 and 6 had the most number of 
locations showing significant improvements in retinal sensitivity.  In subject 3, peak improvement 
occurred earlier than in other subjects at 4 months, with improvement declining considerably by 12 
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months.   However, at 36 months follow-up, although the number of locations showing significant 
sensitivity improvement was considerably less than at 4 months, the mean decibel sensitivity of the 
locations with remaining improvement was maintained, indicating that focal improvements can be 
sustained.  In addition, the number of locations with a reduction in sensitivity was greater in the 
control eye of subject 3 compared to their study eye, perhaps suggesting a protective effect on rod 
function following therapy.  Subjects 5 and 6 also showed improvements in a few locations in their 
control eyes, with the timing of improvement and decline similar to their respective study eyes.  The 
significance of these findings is uncertain and improvements in the control eyes have not been 
reported in the other trials. 
The same 6 subjects also showed improvement in retinal sensitivity with microperimetry testing.  
Subjects 5 and 6 had the greatest improvements, however peak improvement was only maintained 
in subject 5 at 24 months follow-up.  Although subject 3 showed evidence of maintained sensitivity 
improvement at specific loci with dark adapted perimetry, this was not the case with microperimetry 
testing with sensitivity declining to 0dB at 36 months.  No significant improvements in sensitivity 
occurred in the control eye with microperimetry testing. 
5 out of the 6 subjects who showed improvements with dark adapted perimetry and microperimetry 
testing, also showed improvements in visual mobility assessment. Postoperatively, 4 of these 
subjects were able to navigate the mobility maze at low light levels which they were unable to 
perform at prior to treatment, and made fewer errors when using the study eye.  
Out of the 6 subjects who did not show improvement in any of the investigations, 3 of them had the 
lowest baseline visual acuities and received the lower treatment dose. The other 3 subjects who did 
not respond, received the higher dose but had the most severe predicted mutation effects as a 
result of either their homozygous nonsense or homozygous splice mutations.  In contrast, the 2 
subjects with the most pronounced improvements had mild predicted mutation effects from 
homozygous Y368H missense mutations, and received the higher dose.  A surprising result was that 
in the 2 younger subjects aged 6 and 10 who showed some improvement, the degree of 
improvement was considerably less than in the older subjects who also received the higher 
treatment dose.  This finding is in contrast to the results from the Maguire group which suggested 
that greater improvements occurred in younger subjects.    
A limitation of this study is that by being a non-comparative interventional case series, there was not 
a sham treatment arm. However, it was decided that were subjects to undergo a vitrectomy and 
sham injection in the fellow eye, then this would involve an inappropriate level of risk – namely the 
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well reported potential complications of pars-plana vitrectomy which include infection, retinal tears, 
retinal detachment and cataract formation. In addition, as RPE65 LCA is a relatively slowly 
progressive condition and that as subjects were to undergo repeated baseline assessments (and 
follow-up assessments), it was felt that any significant change in retinal function following treatment 
would be greater than that what would expected from natural disease progression or test-retest 
variability. Further support for the decision to not inject the contralateral eye is derived from animal 
studies which demonstrated that visual function in eyes that were treated with a sham injection, 
were similar to baseline measurements (120). 
 
In summary, this trial provides support for the safe use of an AAV2 vector in retinal gene therapy 
with no serious immune related adverse events occurring.  Fifty percent of subjects showed 
evidence of improved retinal function following treatment, although peak effects were generally not 
sustained.  Retinal thinning in subjects undergoing foveal detachment was a consistent finding 
following surgery in keeping with the findings of the Jacobson group, and was associated with a 
reduction of visual acuity in the study eye.  The number of subjects showing improvement in visual 
function is lower in our group than in the two US groups. This difference may reflect differences in 
the intervention and assessments of outcome.  Although several differences in the treatment 
strategies exist between the 3 groups, one particular difference is the RPE specific promoter used in 
our trial.  As this is primarily a safety study, it was considered appropriate in this initial trial to limit 
expression to RPE cells, rather than use a more ubiquitous promoter expected to drive expression 
inappropriately in additional cell types.  There is a suggestion that mutation type and treatment dose 
had an effect on efficacy in our study, with subjects with the least severe predicted mutation effect 
and those receiving the higher dose having greater levels of improvement in retinal function.  This 
finding was not consistent with the results of the other two groups, suggesting that mutation type 
and dose may only have an influence on efficacy when using a promoter which results in lower 
expression levels.  This may also explain why older patients had greater improvements in our study, 
as the more extensive degree of retinal degeneration may consequently lessen the RPE65 
requirement in older subjects. Putatively this is met by the level of expression achieved by a RPE65 
specific promoter, which may not be the case in younger subjects who potentially have greater 
levels of RPE65 requirement. 
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4.1.2 Maguire/Bennett Group 
One of the 3 initial RPE65 gene therapy trials was conducted at the Children’s Hospital of 
Philadelphia by the Maguire/Bennett group (110).  In this study, 12 subjects (aged from 8 – 44 years) 
underwent three-port pars plana vitrectomy and administration of subretinal AAV2-hRPE65v2, with 
foveal involvement in 9 subjects.  This vector contained a chicken β-actin promoter for expression of 
the human RPE65 cDNA with an optimised Kozak sequence. Three different dose levels were used: 
1) low dose of 1.5x1010 vector genomes in 150µL in 3 subjects; 2) medium dose of 4.8x1010 vector 
genomes in 150µL in 6 subjects; and 3) high dose of 1.5x1011 vector genomes in 300µL in 3 subjects.  
Follow-up for this study has been reported up to 2 years. 
One subject was noted to have an outer lamellar cyst at day 5 on OCT imaging, which progressed to 
a full thickness macular hole at day 14.  This subject already had a poor preoperative acuity and was 
not aware of any deterioration in acuity after development of the macular hole, and there has been 
no reported increase in the macular hole size since. 
No serious adverse effects were reported in any subject.  An increase in neutralising antibody (NAb) 
titre to AAV2 was observed during the first 30 days in 1 subject in both the low and medium dose 
groups, and in 2 subjects in the high dose group.  At day 90, 1 subject in the low dose group, and 2 
subjects in the medium dose group had elevated NAb, with levels remaining elevated in one of the 
medium dose subjects at 1 year follow up.  Tear samples were transiently positive at low levels for 
vector DNA sequences in 1 low dose subject, 2 middle dose subjects and 2 high dose subjects, with 
no positive result detected after day 3.  There was no reported evidence of systemic dissemination 
of the vector sequences in any of the low or middle dose subjects.  However, in 2 of the 3 subjects in 
the high dose group, peripheral blood mononuclear cells were mildly positive for vector sequences 
up to day 3 postoperatively.  There was no evidence of T cell responses to the AAV capsid. 
Significant improvement in visual acuity was reported to occur in 7 out of 12 subjects, aged 10 to 26.  
These occurred in 3 subjects in each of the low and medium dose groups, and in 1 subject in the high 
dose group.  The range of improvement was from 0.16 to 0.56 logMAR, with a mean improvement of 
0.48 logMAR.  However, the mean baseline acuity of the majority of patients with improved acuity 
following treatment was poor (1.46 logMAR), and the test-retest variability in such patients is 
underdetermined.  Of note, the subject who developed a macular hole following surgery was also 
one of the subjects with a significant improvement in post-treatment visual acuity.  This finding is 
not expected and illustrates the variation in visual acuity amongst patients with poor vision.  One 
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subject experienced a worsening in visual acuity from 1.35 logMAR at baseline to 1.83 logMAR at 1 
year follow-up. 
Improvement in Goldmann Visual Field perimetry was reported in all 12 subjects.  However, the 
actual amount of improvement in a substantial number of these subjects is marginal, with 
approximately only 5 subjects having clear demonstration of improvement – albeit without the 
details of the non-treated eye available for comparison. 
One conclusion of this group’s study is that the greatest improvements were seen in younger 
children – based on investigations including full-field dark adaptometry sensitivity threshold (FST) 
testing and pupillometry.  With FST testing, 5 out of 7 subjects tested showed a significant 
improvement in sensitivity in their treated eye.  In a comparison of younger (8-10 years) and older 
(20-24 years) subjects who both received the middle dose, greater improvements were seen in the 
younger subjects, in which one subject attained almost a 20dB interocular sensitivity difference post 
treatment, compared to a maximum 8dB difference in the older group.  However, the greatest 
interocular sensitivity difference of approximately 30dB was attained in a 35 year old subject who 
received the higher dose, illustrating that significant improvements can also be obtained in older 
subjects. Of note, peak improvement in sensitivities were generally not maintained with 5 out of 7 
subjects achieving their peak response within 100 days post-treatment, and only 2 subjects 
maintaining peak FST levels after 100 days.  11 out 11 subjects investigated with pupillometry testing 
showed significant improvement following treatment.  Four younger subjects aged between 8 and 
11 showed the greatest change of 2 to 3 log improvements in light sensitivity at 90 days post-
treatment.  However, significant improvements of 2 log light sensitivity were also seen in three older 
subjects with a mean age of 29 years, again questioning the conclusion that the treatment is more 
efficacious in younger subjects. 
Four young subjects aged from 8 to 11 years are reported to have improvements in mobility testing 
following treatment.  However, baseline details of the time taken to navigate the obstacle course 
and the numbers of errors made are not provided, making it difficult to evaluate the post operative 
results.  
No differences in the degree of response to treatment were noted between the doses administered 
or by the subject’s mutation type. 
In summary, this trial has provided support for the safe use of AAV mediated gene transfer in 
humans, and subsequent improvement in visual function, particularly demonstrated by 
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improvements in FST and pupillometry.  There is uncertainty as to the significance of visual acuity 
improvements reported and whether younger subjects responded more favourably to the therapy.  
4.1.3 Jacobson Group 
In another of the three initial RPE65 gene therapy trials conducted by the Jacobson group, 15 
subjects age 11 to 30 years of age underwent vitrectomy and administration of subretinal AAV2-
hRPE65v2 with a chicken β-actin promoter also used.  4 different doses with 2 injection strategies 
were used in 5 cohorts, each containing 3 subjects.  Cohort 1 received 5.96x1010 vector genomes in 
150µL; cohort 2 received 11.92x1010 vector genomes in 150µL; cohort 3 received 8.94x1010 vector 
genomes in 225µL and cohorts 4 and 5 both received 17.88x1010 vector genomes in 2x225 µL 
injections.  Foveal involvement occurred in 5 of 15 subjects and follow up has been reported from 1 
month to 3 years post-therapy (111). 
No serious immune responses were detected following therapy.  2 subjects had elevated levels of 
circulating antibodies to AAV2, possibly consistent with a response to the vector, although 
coincidental exposure to wild-type AAV2 is also considered as an explanation of these rises.  No 
vector genome copies were detected in peripheral blood samples.  
Surgical complications included one subject having a retinal detachment one day after the retina was 
deemed attached – this subject required an uneventful secondary procedure, with no further 
problems reported.  Another subject was noted to have choroidal effusions 3 days after surgery.  
Initial topical therapy with cycloplegics and steroids were unsuccessful, and oral steroids were 
administered, with final resolution of the choroidal effusion not occurring until day 238.   
Visual acuity improvement of more than 0.3 logMAR occurred in 2 study eyes only, both of whom 
had preoperative extra-foveal fixation and also had the lowest baseline visual acuities. In both 
subjects the injection area included the extra-foveal fixation site. One subject had a reduction in 
acuity of over 0.3 logMAR. 
Significant foveal thinning occurred in 4 study eyes, either at short-term or long-term follow-up.  The 
largest reduction in foveal thickness of over 50 microns occurred in one subject with foveal 
involvement, with thinning noted during the early postoperative period and persisted at long-term 
follow-up.  In another subject who also had foveal detachment, foveal thinning occurred in the 
short-term, but had resolved at long-term follow-up.  Conversely, 2 other patients only had foveal 
thinning in the long-term, in one of whom the subretinal injection involved the fovea.  Analysis of 
the retinal laminar architecture across the fovea showed that disturbance of the photoreceptor 
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inner and outer segments occurred in subjects with foveal detachment, and of note, the subject with 
the most significant visual acuity reduction after treatment also had the most prominent foveal 
abnormalities post therapy.  In addition, the 2 subjects with the greatest reduction in foveal 
thickness had the greatest baseline foveal thickness, perhaps suggesting that greater foveal 
photoreceptor loss can occur in subjects with potentially the most photoreceptors to lose.   
Using full-field stimulus testing with both blue and red flashes to stimulate rod and cone responses 
respectively, significant improvements were seen with both stimulus types.  Post-treatment 
sensitivity to blue light was significantly greater in the study eye compared to the control eye, with 
14 out 15 study eyes showing improvement in rod function with a mean increase of 1.59 log10.   All 
15 of the study eyes showed an improvement in cone sensitivity with red stimuli, with mean 
improvement of 0.45 log10.   In the 9 subjects with over 12 months of follow-up, improvement from 
baseline was maintained in all 9 subjects with rod function testing, and in 5 subjects with cone 
testing.  However, peak sensitivity in rod function occurred at final follow-up visit in only 2 of the 9 
eyes, and in only 1 of the 5 eyes who showed cone function improvement, indicating that maximum 
treatment effect may not have been sustained.  
Significant improvements were also found with pupillometry testing in the study eye, with this group 
showing a mean improvement of 1.17 log10, and 9 of 14 eyes tested having greater than 1 log10 
improvement.  No significant effect of age was found on the degree of pupillometry improvement, 
and similarly age did not appear to be associated with improvements in visual acuity of full-field 
stimulus testing.  
Static dark-adapted visual field testing was performed to help identify the location of sensitivity 
improvements.  In 11 of the 12 subjects investigated, the loci of visual field improvement 
corresponded with the subretinal injection site.  In one subject, visual field improvement of more 
than 8dB sensitivity was only found in the temporal periphery, despite central-superior injection 
location.  In several other subjects, the area of visual improvement extended outside that which 
would be predicted by the region covered by the injection. 
Six subjects underwent both pre and postoperative mobility testing, and better performance post-
treatment was observed in 3 study eyes, one of which was only apparent at the lowest illumination 
level of 0.2 Lux, whereas the other 2 subjects had improvements at 0.6, 2 and 4 Lux levels also. 
In summary, this trial has provided further support for the safe use of AAV mediated gene transfer.  
Treatment can lead to improvements in both rod and cone function, with age, mutation or vector 
dose not appearing to have an effect on the degree of improvement that occurred.  Some concerns 
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about the effect of foveal detachment are highlighted, with significant foveal thinning occurring in 2 
out of 5 subjects with foveal involvement.  In addition, significant visual acuity reduction occurred in 
1 subject who also had the greatest degree of foveal thinning and adverse retinal structural changes 
after treatment.  In view of the general lack of improvement in visual acuity, combined with the 
adverse visual acuity and foveal structural changes, the group suggest that the fovea should not be 
included in subretinal injections unless 1) there is OCT evidence of foveal atrophy or 2) extra-foveal 
fixation is determined preoperatively.  This study was the only one to use more than a single 
injection site, with 6 subjects receiving both a superior retina and nasal retina located injection.  In a 
modification of their injection strategy, they suggest that in cases where it is advisable to not involve 
the fovea, 150µL of the vector could be injected at 3 locations: superior retina, nasal-superior retina 
and temporal retina, to enhance the area of potential retinal function improvement. 
 
4.1.4 Overall Results Discussion 
Despite several differences in the study design of the 3 initial RPE65 gene therapy trials, it is possible 
to collectively assess the results, and draw some general conclusions to date. It appears that 
subretinal delivery of AAV2 carrying RPE65 is immunologically safe, with no serious concerns raised 
in this aspect. There is evidence of improvement in retinal function in 33 out of the 39 patients 
treated. However, the level of improvement has not been sufficient to enhance ERG function, nor 
significantly and consistently improve visual acuity or subjective visual experience. Therefore, for 
RPE65 gene therapy it is reasonable to consider excluding the fovea in the treatment area until more 
substantive improvements can be obtained through the optimisation of vectors.  Multiple injections 
of smaller vector volumes is one alternative approach to maximise the treatment area whilst 
minimising any possible photoreceptor degeneration from bullous retinal detachment, though this 
might increase the risk of intraoperative complications. 
The use of a chicken β-actin promoter resulted in some degree of improved visual function in all the 
subjects that it was used, compared to half of subjects who received the RPE65 specific promoter.  In 
view of the lack of significant immunological or clinical concern from using either of the promoter 
types, it could be proposed that a chicken β-actin promoter is a more effective promoter type to use 
in RPE65 deficiency – although the results obtained with this promoter in humans are still below 
those obtained in animal models which showed significant ERG improvements. Future vector 
optimisation work to obtain expression levels that result in ERG improvement will provide strong 
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support for foveal involvement as the benefits of visual function gain will most likely outweigh the 
risks from any potential iatrogenic adverse events. 
The maximum levels of improvement in retinal sensitivity appear not to be sustained in all three 
trials, suggesting that the treatment effect may lose efficacy over time.  It is possible that RPE65 
expression levels are not maintained, or that continued natural disease progression negates any 
continued RPE65 expression.  The fact that reductions in sensitivity from peak values can occur over 
a period of a few months suggests that expression levels not being maintained is the reason for 
declining improvement, rather than it being attributable to disease progression.  Without 
performing histological analysis from treated subjects, it is difficult to be certain of levels of gene 
expression and whether they are maintained in the long term.  The mechanism for a possible decline 
in gene expression is uncertain but possible explanations could include an as of yet undetected 
immune related form of down-regulation or disruption of the viral genome.  It is too early to be 
certain whether the treatment is having an effect on the rate of slowing disease progression, with 
further follow-up required to address this important question. 
In conclusion, the demonstration of improved visual function following vector administration 
represents significant proof of principle for gene therapy in inherited eye disease. There is 
considerable scope to build on these findings for the benefit of people with sight loss caused by 
defects in RPE65 and other genes 
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4.2   Retinal structure and function in Achromatopsia 
In preparation for a gene therapy trial, the purpose of this study was to gain further understanding 
of the retinal structure and function in ACHM, and any association with age or genotype, thereby 
helping to identify potential patients who may benefit from intervention and time-points which this 
may be appropriate. 
In contrast to recently reported case series (58, 59), our cross-sectional study (n=40) has not found 
an age-associated loss of cone structural integrity in patients with ACHM.  No significant differences 
were found in the ages of patients with the aforementioned various SDOCT changes (section 3.2.2), 
and furthermore, patients without ISe disruption had the second highest mean age of the five 
SDOCT categories.   
In a study involving 40 patients with ACHM, Thiadens et al. (55) reported that cone loss occurred in 
42% (n=8) of patients who were under 30 years of age, with 95% (n=20) of patients over 30 years 
showing cone loss on SDOCT (58).  In contrast, we found that cone loss (SDOCT categories 3 to 5) 
occurred in approximately 50% (14/27) of patients less than 30 years of age, but in only 30% (4/13) 
of patients aged over 30 years.  In addition, we found that the proportion of patients with any 
disruption in cone structure (SDOCT categories 2 to 5) to be less than other studies, with 48% of 
patients having ISe disruption in our study, compared to 70% reported by Thiadens et al., 100% in 
the smaller Thomas et al. study (n=13) (59), and in 83% of patients in the Genead et al. study (n=12).  
Similarly, Thiadens et al. identified a HRZ in 60% of patients, with Thomas et al. reporting a HRZ in 
54% and in 58% with Genead et al., compared to 23% in our study.  One possible explanation for the 
difference in incidence of OCT changes and their severity across these studies includes a common 
feature of inherited retinal disease, namely the considerable phenotypic heterogeneity that is often 
characteristic.  This is further illustrated by the family with GNAT2 mutations in our study; with the 
youngest member aged 29 showing a HRZ, in contrast to his father aged 52 who had no ISe 
disruption. 
Further evidence supporting the notion that an age-dependent deterioration in cone structure 
occurs in ACHM is provided by a longitudinal study which performed OCT imaging in 8 subjects on 
two occasions, with a mean follow-up of 16 months (121). In this study, all 5 of the younger subjects 
(aged less than 10 years) showed alterations in foveal cone morphology at the second visit, which 
included IS/OS disruption and HRZ development. This is in contrast to the 3 older subjects (aged 
between 42-45 years) who did not show changes in cone structure at the second visit.  
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In a further study, which utilised autofluorescene imaging in ACHM patients, age-dependent changes 
were found with younger patients exhibiting areas of foveal and parafoveal hyper autofluorescence, 
whereas older patients showed punch out regions of hypo autofluorescence which corresponded 
with areas of cavitation on OCT (122).  
In view of these results however, it is important to state that progression does not imply that age 
alone should be the principle criterion for emerging trials; in other words different patients likely 
progress at different rates. 
We did not identify any significant decline in visual acuity, contrast sensitivity or reading acuity with 
advancing age in our study, and to the best of our knowledge, this is the largest study to date 
reporting on any potential change in these parameters with age.  We did however find a decline in 
retinal sensitivity with microperimetry with advancing age.  A significant reduction in retinal 
sensitivity , determined by mesopic microperimetry, has been reported to occur in normal subjects 
with increasing age, with a 1dB lower retinal sensitivity found in subjects aged 70 to 75 years 
compared to those aged 20 to 29 years (123).  A decline in retinal sensitivity of 3.1dB was observed 
in our study between patients less than 25 years of age (n=22) and those over 25 years (n=18), 
raising the possibility that the reduction was over and above that potentially attributable to natural 
age-related decline.  In our cohort of patients with absent cone function (on the basis of 
electrophysiology and psychophysics), it is presumed that retinal sensitivity detected by mesopic 
microperimetry testing is a consequence of retained rod function. This raises the question as to 
whether rod function declines in patients with ACHM with age and if so, why? If there is no change 
in rod function, it remains a possibility that there is residual central cone function in some subjects, 
which may deteriorate over time. A future study is required to probe which class of photoreceptor(s) 
underlies the retinal sensitivity detected by mesopic microperimetry in patients with ACHM – for 
example determining the rate of recovery of retinal sensitivity using the aforementioned 
microperimeter following a full bleach might help to shed light on this intriguing issue.  A mean 
retinal sensitivity of 16.6dB was found in our study, and this was higher than that reported by 
Genead et al. in which only 4 subjects underwent microperimetry testing and had a mean sensitivity 
of 12dB. 
We did not observe a clear association between retinal structure and function, with no differences 
identified in visual acuity, contrast sensitivity, retinal sensitivity or fixation stability between patients 
with the various aforementioned SDOCT or fundus changes (section 3.2.1 and 3.2.2).   This is in 
keeping with the lack of an association reported between the presence of an HRZ and visual acuity in 
previous studies (58, 59).   Surprisingly, patients without ISe disruption had a significantly (p=0.02) 
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lower reading acuity compared to patients with SDOCT changes - however, a significant difference 
was not found in any other parameter, so this may be a spurious finding.  
Foveal hypoplasia (defined as the persistence of one or more inner retinal layers through the foveal 
centre) was noted on SDOCT in 52.5% (n=21) of patients in our study. In contrast, foveal hypoplasia 
was defined as the presence of multiple ganglion cell layers by Thiadens et al. and noted in 80% of 
their patients (58).  In the Thomas et al. study, foveal hypoplasia was defined as the continuation of 
the OPL and IPL at the fovea, and found in 69% of their patients (59), and if the same definition was 
used in our study, foveal hypoplasia would be present in 60% (n=24) of patients.  Importantly, we did 
not find any significant differences in visual acuity, reading acuity or fixation stability in patients with 
or without foveal hypoplasia; however, significantly better contrast sensitivity and retinal sensitivity 
were found in patients with foveal hypoplasia. 
In the majority of cases no definite correlations were observed between retinal structure or function 
and genotype.   Mean retinal sensitivity was marginally, but significantly (p=0.04) higher amongst 
CNGB3 compared to CNGA3 patients.  A similar number of CNGA3 patients (n=9, 52.9%) and CNGB3 
patients (n=9, 60%) had milder outer retinal disturbance (grade 1 or 2) on SDOCT; with 1 patient in 
both of these groups also having the most severe grade of SDOCT structural damage.  Visual acuity, 
reading acuity and retinal sensitivity were lower in patients with either GNAT2 or PDE6C mutations, 
however the number of patients with either of these mutations was small, 4 and 1 respectively, and 
their ages generally higher than in the CNGA3 or CNGB3 groups, thereby limiting the ability to make 
reliable comparisons.    
4.2.1 Implications for gene therapy 
From our results, we propose that the potential window of opportunity for gene therapy 
intervention for patients with ACHM may be larger than recently suggested.  We did not find an age-
related association with disruption or loss of cone photoreceptors, with the age of patients with no 
ISe disruption ranging from 6 to 52 years of age.   
As this was a cross-sectional study, it has not assessed whether patients who have any form of outer 
retinal change, continue to show progression, and if so, how variable is any rate of change.  With 
respect to cone photoreceptor structure, we therefore suggest that patients who are being 
considered for potential gene therapy intervention are assessed on an individual basis, irrespective 
of age.  In addition, we did not find that visual function was worse in patients with foveal hypoplasia, 
in fact significantly better contrast sensitivity and retinal sensitivity were found in patients with 
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foveal hypoplasia, suggesting that foveal hypoplasia per se should not be an exclusion criterion for 
potential therapy trials.  
In addition to the integrity of cone photoreceptor architecture, another factor likely to influence the 
extent of a potential response to gene therapy is the ability of the higher visual system to respond to 
newly acquired cone activity.  Functional magnetic resonance imaging has shown evidence of visual 
cortex reorganisation, with the area of visual cortex normally active following cone-derived foveal 
stimulation, being active instead following rod stimuli in ACHM patients (n=3) (124).  To what degree 
and up to what age the visual cortex is able to adapt to and process input from cone photoreceptors, 
is an important consideration and will likely have bearing on the efficacy of gene replacement 
therapy. 
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5. Conclusions 
The last decade has seen major advances in several key disciplines, including improvements in 
molecular genetics allowing identification of disease-causing mutations and viral vector gene 
transfer technology, which have enabled the commencement of the first human trials of gene 
replacement therapy for RPE65 deficient inherited retinal disease.   
These trials have demonstrated the safety of AAV administration in the eye, with no serious 
immune-related consequences.  These trials have also demonstrated that improvements in retinal 
function can be achieved and provide encouragement for the consideration of applying gene 
replacement therapy to other retinal dystrophies. The extent of species-specific differences is 
reinforced by the common finding that the impact of RPE65 gene therapy appears less strong in 
human subjects than in preclinical models.  
In addition, although subretinal vector delivery is at present the most effective way of transducing 
outer retinal layers, a number of patients have experienced retinal thinning as a consequence, which 
in some cases has been associated with a decline in visual acuity when the fovea has been included 
in the injection region.  To improve on the results of these current RPE65 trials, increased levels of 
expression by vector optimisation may provide therapeutic benefit to the fovea that can more than 
compensate for the predictable adverse effect of retinal detachment, as is evident outside the 
macula.   
In contrast to LCA due to RPE65 mutations in which the RPE is the primary site of dysfunction, ACHM 
is a disorder of purely cone photoreceptor function and as the highest concentration of cone cells is 
situated in the foveal region, for significant improvement following gene therapy to be achieved, it 
will be necessary to include the fovea in the subretinal treatment region.  However, it is feasible that 
transduction of a significant proportion of cone cells can be achieved by delivery of a considerably 
smaller injection volume than that used in the RPE65 trial, thereby potentially minimising iatrogenic 
photoreceptor degeneration. In addition, foveal function is essentially non-existent in ACHM 
patients, therefore there is minimal scope for harm to function with sub-foveal injection. This ACHM 
study has also reiterated a common feature amongst inherited retinal diseases, namely the 
considerable phenotypic variability that can exist within conditions.  With ACHM, a clear association 
between age and cone outer photoreceptor structure has not been demonstrated, with several 
patients in their third decade showing no disruption in cone structure.  This implies that the window 
of opportunity for gene therapy intervention is potentially larger than has been suggested recently, 
and subjects need to be assessed on an individual basis, irrespective of their age. 
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With work progressing towards the development of gene vectors for a variety of other inherited 
retinal diseases, and studies helping to identify appropriate patients and time points for 
intervention, the next decade offers opportunity for significant advancement in the understanding 
and management of these debilitating and as of yet, untreatable conditions. 
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